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Drug delivery techniques are an integral component in modern medical practices. 
Numerous drugs have been designed to exploit drug delivery systems, primarily oral 
administration, as it is preferred by the public for treatment of animals and humans. 
Butorphanol is a commonly used opioid analgesic drug for pain relief in avian species. 
The pharmacokinetic reports on butorphanol suggest that it is metabolised and cleared 
from an avian body at a much faster rate when compared to mammals. A single 
intravenous injection of butorphanol at 2 mg/kg provides analgesia for only 2 hours. 
When given at higher doses, butorphanol starts to produce side effects such as 
hyperventilation, cardiac insufficiency, coma and death. Therefore, there is a need to 
develop a slow release drug delivery system for butorphanol which can prolong the 
duration of analgesia without the side effects. Hydrogels are an emerging drug delivery 
strategy which can release drugs at a controlled rate and overcome many of the problems 
with traditional delivery techniques. This controlled delivery is vital for prolonged 
delivery of drugs which can be hazardous when applied in higher doses such as 
butorphanol. However, many modern hydrogels lack the stability for prolonged drug 
release or present other problems including prohibitive cost and bio-incompatibility. In 
order to solve these problems and improve the delivery system, hydrogels were developed 
using nanocellulose derivatives coupled with traditional hydrogel materials.  These 
systems allowed slow sustained release of butorphanol in broiler chickens species with 
limited observed side effects due to the biocompatible nature of the hydrogels. The 
hydrogels provided an analgesic effect for up to 26.5 hours which was a longer time than 






2. Literature review 
2.1 Nanocellulose 
2.1.1 Nanocellulose forms 
Cellulose is a linear chain polysaccharide composed of multiple β-(1,4)-glyosidic linked 
D-glucose units9, and is an important structural component of the cell walls in algae, 
bacteria fungi, tunicates and plants. It can only be digested naturally by ruminants with 
specialised symbiotic microorganisms present in the gastrointestinal tract, specifically the 
rumen capable of breaking down the cellulose via fermentation reactions.  
In recent years, interest in nanocellulose has increased due to 
its biocompatibility associated with its similarity to the human 
extracellular matrix, biodegradability and stability. In 
addition, its ability to form hydrogels and be chemically 
modified makes it an ideal material for use in biomedical 
applications.   The two primary sources of nanocellulose are 
from plant matter such as wood pulp, cotton or hemp fibres 
(Fig 1), and bacterial sources such as Gluconacetobacter 
xylinus (G. xylinus).  
There are three primary forms of nanocellulose currently being investigated: cellulose 
nanofibrils (CNF), cellulose nanocrystals (CNC) and bacterial nanocellulose BNC. CNF 
is extracted from wood pulp. It has a strong tensile strength, is capable of forming 
hydrogels and is currently used as a stabilising agent for food product. CNC is produced 
by acid treatment of native cellulose, preserving the crystalline areas, resulting in rod-like 
structures with a high specific strength. They are useful for mechanical stability and drug 
delivery systems.  BNC is primarily produced by G. xylinus. It has a high tensile strength 
and a hydrophilic surface making it useful for drug delivery systems and tissue 
scaffolding for tissue engineering.10 Images of these three forms are shown in Figure 2. 
 
Figure 1: Untreated hemp fibres. 
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Figure 2: Images of CNF (a), CNC (b) viewed by transmission electron microscopy and BNC (c) viewed via scanning electron 
microscopy.10 a shows the CNF units with 1-3 µm length and 2-60 nm width. b shows CNC with 10-50nm width and 100-500 nm 
length9. c shows BNC with 5-70 nm width and 100 nm length.11 The weblike structure of the CNF and BNC and the rod-like structure 
of the BNC influence their binding characteristics. 
The bulk of the literature currently available on nanocellulose hydrogels and their 
biomedical applications has focused on using the nanocellulose as a biological scaffold 
and/or drug delivery system for wound treatment due to its biocompatibility and 
mechanical properties.12  
While many papers have shown the potential of nanocellulose hydrogels as drug delivery 
systems, few have produced complexes capable of releasing the drugs with a steady 
release rate using opioids, and even fewer studied for the use of hydrogel subcutaneous 
drug delivery systems in avian animal models.  
2.1.2 Cellulose nanocrystals 
 Cellulose nanocrystals are prepared from woody materials such as cotton or hemp fibres. 
The fibres are then degraded using chemical or mechanical treatments (collectively called 
the top down approach) where the large quantity of starting material is sequentially 
broken down to remove waste material such as ligands and lipids.   
The mechanical processes can involve high pressure homogenisation, high powered 
sonication and micro fluidisation techniques in order to apply shear stresses to the 
cellulose fibres, splitting them along the longitudinal axis in order to produce strings of 
cellulose crystals with disordered crystalline regions acting as linkages. 
Chemical processes such as acid hydrolysis transform microfibrils of cellulose into 
crystalline nanocellulose with lower energy requirements than the mechanical treatments 
which produce short nanocrystals with improved crystallinity. The acid hydrolysis 
method uses strong acids to destroy the amorphous domains of the microfibrils while 
preserving the ordered crystalline sections.  
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Once the monocrystalline cellulose is isolated it can then be further modified to produce 
multiple forms of the rigid rod-like cellulose nanocrystals which possess many important 
properties such as high strength modulus, a large surface area and unique liquid 
crystalline properties.13 
Nanocrystals are less suitable for drug delivering hydrogels than cellulose nanofibrils and 
bionanocellulose. This is due to the more rigid structure producing weaker 3D matrices 
that are potentially useful for developing flexible electronics displays and advanced 
battery systems. 
2.1.3 Nanofibrillated cellulose 
The primary form of nanocellulose produced by the top down approach is nanofibrillated 
cellulose from plant matter via mechanical or chemical treatments similar to those 
described in 2.1.4 in order to produce a 3D matrix of flexible and entangled chains of 
cellulose units. The properties do however differ from the other forms of nanocellulose 
by possessing a low gas permeability rate and a higher tensile strength allowing for a wide 
range of potential applications.  
The material can then be further processed with chemical modifications for a wider 
variety of applications ranging from topical application of antibiotic drugs for wound 
treatment through to producing paper with improved sheet tensile properties.  
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2.1.4 TEMPO oxidation 
TEMPO oxidation (Fig 3) is a potential technique for the extraction and modification of 
nanofibrilated cellulose using chemical treatment of cellulose microfibrils to add negative 
charged entities to the fibre surface. 2,2,6,6-Tetramethylpiperidine-1-oxyl (TEMPO) is a 
highly stable catalyst which uses NaClO and NaBr to oxidise the primary alcohol groups 
on the cellulose fibres in order to produce carboxylate groups (COO-) in aqueous solutions 
with a primary oxidising agent (NaClO). The reaction is carried out at pH ≈10 which 
leaves a small percentage of aldehyde groups which have not been completely oxidised 
to form the carboxylate groups.14 
Figure 3: TEMPO oxidation of a primary alcohol to a carboxylic acid with a TEMPO catalyst, NaClO and NaBr suspended 
in water at pH 10.7 
Figure 4: TEMPO oxidised cellulose monomer. 
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The COO- groups provide a negative charge to the surface of the nanofibrilated cellulose 
(Fig 4) making the formation of ionic bonds possible by cross linking molecules such as 
Ca2+ with other negatively charged particles such as the carboxyl groups on sodium 
alginate and or chitosan that has an overall cationic charge.15 
2.1.5 Bionanocellulose 
Bionanocellulose is a form of nanocellulose produced primarily by the bacterial species 
G. xylinus. This species is a rod shaped, gram negative and an obligate aerobe which
metabolises sugars, primarily glucose, to synthesise cellulose. 
Biosynthesis of the microbial cellulose occurs in the space between the outer wall and 
plasma membrane of the bacterial cells via bio-catalytic action of an enzymatic complex 
cellulose synthase with uridine diphosphate glucose (UDP-glucose) as the starting 
material.  The UDP-glucose units are attached to polymeric chains with the reaction 
catalysed by the cellulose synthase.  
Figure 5: Potential biosynthesis pathway for cellulose production.4 
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This reaction has a high turnover rate with a single bacterial cell capable of converting 
greater than 100 glucose molecules into cellulose per hour16. This reaction is believed to 
follow the potential biosynthesis pathway (Fig 5). 
Bionanocellulose is secreted by the bacterial species as an extracellular primary 
metabolite composed of cellulose microfibrils with nano metric widths thereby classing 
it as a nanomaterial due to one of the dimensions possessing a nano level order of 
magnitude.17  
This nanocellulose is considered to be of higher quality than those produced by the 
breakdown of the complex plant matter via the top down approach, despite having the 
same molecular formulae. The bionanocellulose forms dense interconnected networks of 
cellulose chains capable of forming more absorbent and stronger hydrogels. Due to their 
more intricate structure with stronger and larger fibres, the strength of the crosslinking 
and the absorption coefficient are both increased.17 
The limiting factors include the high unit cost, slow growth rates of the bacterium, current 
lack of large scale production facilities and the time intensive processing steps required, 
for example the Cross-Bayer reagent treatment of the cellulose pellicle takes multiple 
days in order to purify the nanocellulose. 
2.2 Nanocellulose based hydrogels for avian analgesic drug delivery 
Modern strategies for drug delivery present a balancing act between the release rate, 
efficiency and safety of the delivery strategy in question. Multiple factors need to be 
considered based upon the drug in question and the vector of administration.  
There are three primary admission vectors for the introduction of drugs into a system: 1. 
the enteral route encompassing oral administration through the gastrointestinal tract 
(GIT), 2. per-rectal administration and 3. the parenteral route encompassing 
intramuscular, intravenous, intranasal, subcutaneous administration and topical 
application.18 
8 
2.3 Enteral routes 
2.3.1 Oral administration 
The oral route is the most common method for administering drugs to animals and 
humans due to its lower costs, the safety of delivery and the ease by which it can be 
applied. This route also presents limitations for the type of drugs available for delivery 
due to the wide pH range the drug must tolerate and the limited exposure time in the 
gastrointestinal tract where uptake is possible. There is also a decreased efficiency due to 
the presence of protecting components and slow uptake making this route impractical for 
rapid administration. Finally, there is a limited amount of drug reaching the desired tissue 
target, due to the initial passage through the liver (also called the first-pass effect). 
2.3.2 Rectal administration 
This is a route used for unresponsive or uncooperative patients where oral administration 
is not feasible. This route also bypasses the gastric acids present in the stomach, the 
lipases and carbohydrates present in saliva, thereby removing design constraints on the 
nature of the drug administration. The disadvantages are primarily around customer 
acceptance and the increased influence of the first-pass effect decreasing the amount of 
drug reaching the portal blood and then entering circulation. 
2.3.3 Sub-lingual and buccal administration 
This route involves the placing of pills beneath the tongue or in the cheek sulcus allowing 
rapid adsorption of the drug while simultaneously decreasing the first-pass effect by 
rapidly crossing the membrane barriers to enter the blood stream. The inconvenience to 
the patient involves the risk of swallowing and therefore removing the drug, with the 
added risk of irritation to the mucosal tissue prevents this drug delivery route from being 
widely accepted. 
2.4 Parenteral routes 
Parenteral is derived from the words ‘para’ meaning to bypass and ‘enteron’ meaning the 
alimentary canal between the mouth and the anus. 
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2.4.1 Subcutaneous injection 
Subcutaneous injections introduce the drug between the skin and 
muscle layers using a short needle, as shown in Figure 6. This 
technique allows drugs to be delivered which would be 
substantially degraded by gastric acid or enzyme activity when 
administered orally to the patient. This type of injection allows for 
a slower release rate of the drug when compared to intramuscular 
injections due to the decreased blood flow rate in the area reducing 
the speed of the uptake rate of the drug into the circulatory system. 
The injection sites are primarily the upper arm, front of the thigh 
and lower abdominal area where there is a more accessible adipose 
layer. This strategy is commonly used to administer insulin.19 
2.4.2 Intravenous injection 
Intravenous injections are the most common parenteral route used by healthcare 
professionals, the drug is administered to the circulatory system immediately and 
adsorbed rapidly with dependable and replicable results. This also bypasses the first-pass 
effect on the drug’s concentration within the system. However, this route can require 
cannulation of a vein which is problematic when patients have small veins. It is in many 
cases more expensive, labour intensive and potentially traumatic while providing an 
avenue for infection and the potential for an inflammatory response.20 
2.4.3 Intramuscular injections 
For intramuscular injection, the drug is administered 
to deltoid, vastus lateralis, ventrogluteal or 
dorsogluteal muscles, as shown in Figure 7. This is 
dependent on the nature of administration (self-
administration or by a healthcare provider), the size 
of the patient (infant, child, adult) and the nature of 
the drug being delivered (viscosity and volume).  
Intramuscular injections are commonly used as a 
parenteral drug delivery route for application of slow release drugs, the tissue slowly 
releases the drug into the blood stream where it is absorbed and then there is rapid onset, 
a high absorption rate and the potential for oily materials to be used. 
Figure 6: Subcutaneous injection 
technique.2 
Figure 7: Intramuscular injection to deltoid.3
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This technique is useful for infants where intravenous delivery is not practical, or for 
patients with collapsed or constricted veins such as habitual intravenous drug users or 
patients undergoing courses of chemotherapy.20 
2.4.4 Topical application 
This route involves absorption of the drug through the skin layers in order to treat surface 
wounds, desensitise the skin or apply protection to the outer skin layers. This method is 
limited in application but is beneficial for treatment of wounds on extremities and can 
provide a mechanism to prevent infection and damage to the internal system. This is 
generally a slow uptake mechanism but is also widely acceptable to the public and does 
not require trained personnel for application such as diclofenac muscle/osteoarthritic 
gels.21 
2.4.5 Intranasal application 
This mechanism is a painless and simple application method which utilises the close 
proximity of the nose-brain pathway in order to deliver the drug rapidly to the 
cerebrospinal fluid. This is especially important for opioid delivery as the opioid receptors 
in the brain and spinal cord are responsible for the analgesic effect. The drugs also bypass 
the first-pass effect of the enteral routes minimising the breakdown of the drug. However, 
there are a limited number of drugs which can be applied this way due to the aerosol 
nature of the delivery and the high drug concentration required for an effective dose.22 
2.4.6 Blood-brain barrier 
The Blood-Brain Barrier (BBB) is a key 
consideration when determining the 
delivery mechanism for opioids and 
other compounds that require access to 
the cerebral tissue to function. The BBB 
is the semipermeable membrane 
between the circulatory system and the 
cerebrospinal fluid present around the 
brain. This barrier is selective and limits 
the passage of microorganisms and large 
molecules based upon the water-levels, 
polarity and the nature of the receptors bound to the drug membranes. 
Figure 8: Three strategies (A, B, C)  for drug delivery through the BBB.1 
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This is important for delivery of analgesics as they require access to the brain in order to 
function, if the drug cannot pass through the BBB it cannot function. If the BBB allows 
a limited amount of drug to pass slowly then the amount of drug that effects the brain will 
be drastically reduced. 
There are a few strategies (Fig 8) that have been developed to deliver drugs through the 
BBB where they would normally be blocked. These strategies can disrupt the BBB itself, 
allowing passage of wanted and unwanted materials through (Fig 8A). Other strategies 
involve combining the therapeutic drug to another compound that can carry the drug 
through the BBB (Fig 8B) or bind to receptors for transport (Fig 8C) without 
compromising the barrier.1 
2.5 Traditional hydrogel materials 
2.5.1 Alginate 
Alginate is the collective name for the group of naturally occurring anionic 
polysaccharides which have been extracted from brown algae strains (Fig 9). These 
include Ascophyllum nodosum, Laminaria hyperborean, Macrocytisis pyrifea and the 
bacterial species Azotobacter and pseudomonas.23  
Sodium alginate (Fig 10) is composed of alginic acid with its sodium salt extracted from 
brown algae belonging to the Phaeophyceae phylum. It is also produced by the 
opportunistic bacterium Pseudomonas aeruginosa where it composes a large amount of 
the biofilm produced to confer resistance to antibiotics and destruction by macrophages. 
The survival of the Pseudomonas biofilm within a human system can lead to the 
development of cystic fibrosis when the immune system is compromised due to previous 
conditions or other diseases present.  
Figure 10: Sodium alginate monomer. Figure 9: Alginic acid. 
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The alginic acid component is composed of a co-polymer of homopolymeric blocks (Fig 
9). These are (1-4)-linked β-D-mannuronate (m) and C-5 epimer α-L-guluronate (n) 
residues which can then be covalently linked together to form various sequences. The 
monomers can be present as blocks composed of consecutive m residues, n residues or a 
mixture of n and m residues. The ability of the co-polymer chains to absorb water into 
the matrix has led to sodium alginate being incorporated into multiple industrial 
applications including food, cosmetic and pharmaceutical. 
2.5.2 Chitosan 
Chitosan is a linear polysaccharide produced from chitin that had been treated with 
alkaline substances for deacetylation of the chitin. The linear polysaccharide is composed 
of the deacetylated β-(1→4) linked D-glucosamine (m) and acetylated N-acetyl-D-
glucosamine (n) randomly assembled together (Fig 11). 
The original chitin is harvested from the shells of crustacean species. The shells are 
processed to isolate the pure chitin from the other biological materials. This process has 
garnered considerable appeal due to the wide availability of crustacean’s shells which are 
a waste product from the seafood industry. This reduces the cost of the raw material and 
does not require new production facilities to produce the amounts required for 
commercial production. Japan is the primary producer of chitin and chitosan products 
with > 100 billion tonnes produced each year accounting for 90% of the global market.24 
Figure 11: Deacetylated chitosan structure composed of deacetylated β-(1→4) linked D-glucosamine (m) and acetylated N-acetyl-D-
glucosamine (n). 
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The chitin is then further processed to form chitosan with the acetamido group turned into 
amino groups (Fig 12) allowing the chitosan to become soluble in water. There are two 
general processes to convert chitin to chitosan. A thermochemical based reaction and a 
biological based reaction using the enzyme, chitosan dehydrogenase. 
One chemical procedure25 involves demineralisation, deprotonation and deacetylation of 
the chitin. The demineralisation step involves prolonged treatment (16 hr) with HCl at 
ambient temperature (28oC) to remove any unwanted mineral components of the chitin. 
The second step is deprotonation which uses NaOH (20 hr) at ambient temperature (28oC) 
to remove any excess protons that may disrupt the deacetylation step.  
The processed chitin is then dried and mechanically degraded to maximise the surface 
area. At this stage pure chitin has been produced. The deacetylation step is the final step 
with the pure chitin treated with NaOH at 65oC for 20 hr to produce chitosan. 
The biological process involves using enzyme chitin deacetylase which catalyses the 
reaction of chitin with water to produce chitosan and acetate (Fig 12). The chitin 
deacetylase is not inhibited by the production of acetate so is not a self-limiting reaction. 
This chemical process requires the use of non-recyclable chemicals and increased 
temperatures to produce the chitosan. The variables in production, such as species of 
crustacean used and difficulties controlling the temperature can lead to large variations in 
the chitosan produced. The biological process uses the enzyme chitin deacetylase and 
water with no additional chemical requirements and a lower ideal temperature of 50 oC. 
Chitin solubility is determined by the percentage of deacetylation and the pH of the 
solution. Chitosan with lower levels of deacetylation (≈ 40%) is soluble in solutions with 
a pH up to 9 and has a lower viscosity.  
Figure 12: Chitin deacetylated to form chitosan and acetate with the catalyst chitin deacetylase.  
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Chitosan with higher levels of deacetylation required lower pH solutions (up to 6.5) to 
remain soluble and has a higher viscosity. The viscosity is also increased with lower 
temperatures.  
Increases in the chitosan concentration of the solution can also affect the viscosity of the 
solution at the same temperature.  
The viscosity is affected by the degree of deacetylation due to the conformation of the 
molecule changing: with higher levels of deacetylated chitosan possessing, highly 
charged molecules form a flexible chain structure. Lower levels of deacetylation produce 
a lower charged compound with a rod-like structure.26 
2.6 Hydrogel drug delivery 
2.6.1 Hydrogels 
Hydrogels are a 3D network of polymer chains forming a hydrophilic complex. These 
can be crosslinked via covalent and/or ionic bonding, van der Waals forces or hydrogen 
bonding. Then stabilisation can occur by physical interactions such as electrostatic 
interactions, hydrophobic reactions and entanglement of the polymer chains. 
A distinguishing trait of the hydrogels is their ability to absorb water, swelling the gel, 
extending the distance between the polymer chains while still maintaining the structural 
integrity. This contrasts with soluble gel materials which disperse into the liquid phase.  
Hydrogel characteristics are dependent on the desired nature of the crosslinking reactions 
and the final properties of the hydrogel. In turn these characteristics are governed by the 
chemical modification of the polymer chains used to promote discrete binding patterns.  
There are numerous polymers currently used to produce hydrogels. The most common 
polymers used are alginate and chitosan as they are affordable, biocompatible and have 
renewable sources. However there are many other natural polymers used including 
dextran, hyaluronic acid, nanocellulose and xanthan as well as synthetic polymers.27 
The swelling nature of the hydrogels and their capacity for large scale water uptake make 
it possible to use hydrogels as drug delivery systems for water soluble drugs including 
non-steroidal anti-inflammatory drugs (NSAIDs) and opioids such as butorphanol while 
maintaining the hydrogel systems structural integrity.28 
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Hydrogels are currently used industrially for production of products ranging from contact 
lenses, advanced wound dressings, scaffolds for tissue engineering and disposable 
diapers. All of these products exploit the natural properties of the gels which include 
biodegradability and renewability of the starting materials.29  
2.6.1.1 Chemical crosslinking 
One of the possible crosslinking reactions between monomers or polymer chains is a 
chemical crosslink which involves the sharing of electrons between the macromolecules. 
This crosslinking reaction involves the formation of covalent or ionic bonds which can 
change the physical properties of the hydrogel by introducing stronger bonds, which in 
turn creates a denser hydrogel and/or introduces crystallinity into the structure.30 The 
melting point, solubility and viscosity can also be altered by varying the degree of 
crosslinking.  
Crystallinity can increase the rigidity of the structure, decreasing its elasticity with the 
associated risk of making the gel brittle. The less elastic the gel, the more susceptible it 
is to shear stress which can damage or rupture the gel matrix causing a rapid release of 
any enclosed drug. However, the increased crystallinity also increases the melting point 
of the gel allowing a wider range of polymer chains to be used in hydrogel formation. 
The viscosity of the gel can make the gel impractical for use in injectable solutions or 
topical creams. The flexibility between the polymer chains is required for the gel to be 
delivered via injections or placed upon fragile tissue, such as burns, without causing 
damage. This decrease in fluidity is caused by the crosslinking restricting the movement 
of the polymer  
The increase in crosslinking will also decrease the solubility of the gel. With more 
crosslinks, the polymer chain binding increases and the gel becomes capable of taking up 
solvents without disrupting the gel matrix.  
Ionic interactions involve the formation of an ionic bond between two species. This 
normally involves binding polymer chains together through a bridging ligand such as 
calcium ions which can bridge two negatively charged groups located on the polymers 
(Fig 13). This bridging forms bonds by the interaction of the negatively charged COO- 
group with the positively charged Ca2+ ion.  
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These bonds are generally stronger and have a non-reversible nature making them ideal 
for producing hydrogels capable of maintaining their structure when placed under 
mechanical stresses. This is ideal for use in products such as wound dressings or artificial 
cartilage where the movement of the patient would degrade weaker gels.  
A common chemical crosslinking reaction used in the formation of hydrogels is the Schiff 
Base reaction.31 This reaction involves the use of an imine to form crosslinking reactions 
between water soluble polymers to form insoluble hydrogels capable of absorbing water. 
2.6.1.2 Physical crosslinking 
Physical crosslinking involves the use of non-covalent bonding to form gel structures 
from polymer chains without forming covalent bonds. These gels can be formed via 
electrostatic interactions, hydrogen bonding, hydrophobic interactions or van der Waals 
forces. 
Electrostatic interactions occur when the positively charged groups on one polymer chain 
is attracted to the negatively charged group present upon another polymer chain without 
creating a constant bond. 
Hydrogen bonding can occur with the hydrogen atoms of one polymer being attracted to 
an electronegative atom present within the other polymer, this forms a strong bond to 
stabilise the hydrogel polymer (Fig 14). 
Figure 13: Sodium alginate crosslinked with calcium chloride to form ionic bonding. 
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Hydrophobic interactions can also promote gel formation when the polymers are 
repelled by the polar water which causes the polymers to condense into a gel structure. 
Van der Waals forces are the sum of attractive and repulsive interactions between the 
polymer chains. If the attractive forces are stronger a bond can form. If enough of these 
bonds are formed a gel structure can result but the distance between the polymers is 
maintained as the closer the polymer chains become the stronger the repulsive force 
becomes. 
These bonds can form naturally between the polymer chains forming a hydrogel or can 
be induced by altering the charge, pH, temperature or water content of the polymer 
solution.  
The nature of these gels is normally characterised by a lower mechanical strength caused 
by the reversible nature of the non-covalent bonds. This can be exploited to produce 
hydrogels that can rapidly degrade, releasing any entrapped drug into the surrounding 
area allowing for targeted release when exposed to different conditions which break the 
bonds.  
Figure 14: Hydrogen bonding between sodium alginate polymer chains. 
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2.6.1.3 Hydrogel classification 
Hydrogel’s can be classified based upon their composition, the nature of the crosslinking, 
the physical structure of the polymer chains and the charge of the monomers/polymers. 
These all affect the physical properties of the hydrogel and can change the hydrogels 
response to external stimuli such as pH, salt content or heat. 
The hydrogel can be composed of natural or synthetic monomers or polymers. If there is 
only one form of polymer present it is a homo-polymeric hydrogel, if there are two 
distinct forms of polymer present it is classed as a co-polymeric hydrogel. If there are two 
or more polymer networks fully interlaced without forming covalent bonds, the hydrogel 
is referred to as an interpenetrating polymer network.  If there are two or more polymer 
networks that are at least partially interlaced without the formation of covalent bonds, the 
hydrogel is referred to as a semi-interpenetrating polymer network (semi-IPN). If the 
networks are not interlaced at all the hydrogel is referred to as a polymeric blend.  
The crosslinking can be either chemical or physical: chemical crosslinking producing 
stronger bonds that are non-reversible; physical crosslinking which has weaker, reversible 
bonds.  
The physical structure of the hydrogel can be amorphous where the chains are randomly 
positioned with no crystallinity present, semi-crystalline where there are regions of the 
hydrogel containing partially ordered sections and hydrogen-bound where there are 
hydrogen bonds between the polymers in the gel forming a stable network. 
The charges on the monomer/polymer can influence the electrostatic interactions between 
regions with alternate charges (positive to negative and vice versa) and the chemical 
bonding to crosslinking agents.  These can change the overall charge of the hydrogel to 
negative where it is described as an anionic gel, no charge where it is neutral, positively 
charged where it is called cationic and when the gel charge contains both positive and 
negative sections it is called and amphipathic hydrogel. 
2.6.1.4 Smart hydrogels 
Smart hydrogels are classified as hydrogels that respond to external stimuli, altering the 
swelling behaviours of the hydrogel. This can be exploited to produce gels which can 
specifically target certain areas such as the lower intestine while being capable of passing 
through the low pH stomach without releasing an encapsulated drug.  
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This form of hydrogel is considered to be a potential future in drug delivery due to its 
selective nature. An example of this has been to produce a gel which selectively releases 
an encapsulate drug when exposed to UV light. The UV light promotes protonation, this 
protonation then alters the pH allowing for the rapid release of an encapsulated drug in 
the illuminated areas directly and in the non-illuminated areas through proton transfer.32 
2.6.2 Opioids 
Opioids or opiates are a class of drugs that reversibly bind to the opioid receptors located 
within both central nervous system and periphery33,33a. The opioids affect the system by 
mimicking three endogenous peptide endorphins which are found naturally within the 
body. The three peptides are β-endorphins, enkephalins and dynorphins. These peptides 
then bind to the opioid receptors to produce an effect similar to morphine by reducing the 
sensation of pain.34 
The opioid receptors in the central nervous system are divided into three main subgroups; 
mu (µ), kappa (κ), and delta (δ) depending on the corresponding endogenous peptides. 
When bound, the drug can be displaced by the µ-opioid receptor antagonist naloxone.35  
Administration of naloxone is therefore commonly used to rapidly treat overdoses of 
opioids and reduce or remove the associated effects including excessive drowsiness, 
slowed breathing and loss of consciousness.36 Opiates are extracted from opium poppy 
Papaver sominiferum originally from the eastern Mediterranean. The main use of these 
opioid alkaloids is as an analgesic for medical and veterinary practices despite the 
addictive properties. 
The opiates can be applied via the intramuscular, intravenous, oral, rectal, and nasal routes 
dependent on the nature of the opioid, the desired effect and the capabilities of the person 
administrating the drugs.  
The person administering the drug is important as the various administration techniques 
require various levels of technical skill. For example, oral administration can be done by 
most of the general public but the ability to inject into a vein requires more specialised 
training to prevent damage to the veins or injection into an incorrect area. 
The most commonly used opiates are morphine and codeine, which are natural alkaloids 
extracted from the opium poppy. Hydromorphone and oxymorphone are examples of 
semi-synthetic opiates which have been derived from natural opiates.  
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Fully synthetic opioids such as pethidine and the fentanyl series, methadone and tramadol 
are also widely used.37 
2.6.2.1 Butorphanol 
Butorphanol tartrate (Fig 15) is a highly hydrophilic synthetic opioid commonly used in 
veterinarian practice for relief of acute pain.38 It can be administered by traditional oral 
and parental routes or in the nasal passage where it is rapidly absorbed and delivered to 
the active opioid receptors within the brain. 
Butorphanol is a kappa receptor agonist and mu receptor antagonist.38 In birds, 
butorphanol is thought to be effective as it is a κ receptor agonist and birds have a higher 
pro- portion of κ receptors compared with other species.39 
The central opioid receptors are divided into five main subgroups; δ, κ, µ, ζ and 
nociception receptors, depending on their effects. For example, the δ, κ, µ receptors are 
linked to the peripheral sensory neurons responsible for pain transmission.  
The level of the primary opioid receptors, δ, κ, µ differ across the animal species. 
Examples of this are shown in Table 1. 
The δ receptors are responsible for analgesic, antidepressant, convulsive and physical 
dependence effects. This physical dependence can cause dramatic withdrawal signs 
associated with opioid addiction when the opioid usage is reduced.  
This means a slow withdrawing period of gradually decreasing opioid doses is required 
for safely ending a patient’s treatment.  
Figure 15: Chemical structure of butorphanol (A) with the peripheral tartrate ligand (B).  
A B 
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μ κ δ 
Frog brain 37% 19% 44% 
Chicken forebrain 58% 25% 17% 
Pidgeon brain 14% 76% 10% 
Junco (passerinve) brain 74% 22% 4% 
Rat forebrain 41% 9% 50% 
Mouse forebrain 25% 13% 62% 
Guinea pig forebrain 25% 50% 25% 
Dog cortex 5% 58% 37% 
Human cortex 29% 37% 34% 
The κ receptors are responsible for analgesic, anticonvulsive, sedative and stress effects. 
The µ receptors are split into 3 subsections: µ1 is responsible for the analgesic effect 
while also causing physical dependence; µ2 causes the majority of the detrimental effects 
including respiratory depression, the euphoric effect associated with addiction and the 
physical dependence; µ3 is responsible for vasodilation where the blood vessels are 
dilated, lowering the patient’s blood pressure. 
ζ and nociceptin receptors are not involved in analgesic effects and therefore are not a 
target of interest for this study. 
One of the main concerns about opioids is when the effective dose requires a high 
concentration close to the lethal dose to be effective. Variations in patient metabolism can 
potentially lead to overdoses due to different tolerance levels and uptake rates.  
Within a model mammalian species (mice), the dose that was lethal for 50% of the test 
sample, LD50, for intravenous administration was found to be 40-57 mg/kg in mice and 
17-20 mg/kg in rats while oral administration had LD50 rates of 395-572 mg/kg and 570-
756 mg/kg respectively.34 
Table 1: Summary of δ, κ, µ receptor percentage ratios in multiple species.6
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2.6.2.2 Avian drug delivery 
One of the prominent differences between the mammalian analgesic effect and the avian 
analgesic effect relates to the types of opioid receptors in their brains. Avian species 
brains have a greater amount of κ receptors compared to the µ or δ receptors associated 
with the mammalian analgesic effect. This means that opioids used on mammalian 
species which possess high numbers of µ or δ receptors are less effective in avian species 
(Table 1). Opioids that are less effective in mammals, such as butorphanol, become more 
potent due to specific targeting with variation depending on the specific avian species.40 
Studies on pharmacokinetics of butorphanol in birds41,41b show that butrphanol is 
metabolized faster in birds and requires slower release techniques, like mini osmotic 
pumps42, polyoxomer gel43, liposomes.44  
Osmotic pumps are small cylindrical implants that do not require an energy source. They 
function by exploiting the osmotic effect, as the extracellular fluid of the patient diffuses 
through the outer semipermeable membrane the osmotic compartment expands. This puts 
pressure onto the inner flexible reservoir where the drug is present. The drug rate of 
release is caused by the osmotic agent instead of the concentration of the drug present. 
This can dramatically reduce the rate butorphanol is released, extending the time where 
the analgesic effect is present but also increases the time until the analgesic effect is 
produced (6-12 hr).42 
Polyoxomer gels are a thermally sensitive hydrogel that can be loaded with butorphanol 
and provide an analgesic effect for a longer period then the commercial solution. However 
the analgesic effect was only sustainable for 4-8 hrs.43 
Binding butorphanol to liposomes to form a liposomal formulation can also be used to 
provide an analgesic effect in avians for 72hr.44  
While these three delivery systems provide possible solutions for long term analgesic 
treatment using butorphanol, they all possess issues that may limit their application.  
The osmotic pumps take a long time to produce an analgesic effect and must be surgically 
removed. The polyoxomer gel provides an analgesic effect for a longer time but is still 
not efficient for longer treatments. The liposomal formulation was effective but is not 
commercially available and requires powdered butorphanol tartrate for preparation. 
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2.6.3 Animal trials 
2.6.3.1 Three R’s 
The key principles for ethical animal testing are replacement, reduction or refinement. 
The three R’s were developed to minimise or remove the suffering of animals for 
experimental testing while still obtaining the required results.45 
Replacement can involve the use of an absolute replacement, such as using a cell line or 
computer program for testing instead of animal models or relative replacement focusing 
upon the sentient nature, rarity or response to pain.  
With relative replacement, more developed vertebrates such as canines or primates are 
replaced with less developed or more common vertebrates such as chickens or rats. The 
replacement of vertebrate species with invertebrate species with fewer sensory receptors 
is also preferable as the discomfort to the animal can be minimised when the pain response 
is not required to be measured.  
Reduction refers to reducing the number of animals required for the experiment while still 
producing sufficiently accurate results by maximising the amount of data obtained per 
animal or minimising the amount of animal replicates required to answer a scientific 
question. 
Refinement focuses on the wellbeing and treatment of the animals instead of changing the 
animal type or number. By improving the living conditions, the distress and discomfort 
to the animal can be dramatically reduced. Examples of this include providing 
temperature controlled areas, abundant food and water sources with areas provided for 
exercise.  
The three R’s not only improve the conditions for the animals but can improve the 
public’s perception of research involving animal testing and dispelling the pre-
conceptions of animal cruelty present within society.  
With the inadequate correlation between animal model responses and human responses 
the development of absolute replacements becomes more important, especially within the 
pharmaceutical industry. This is because the development process takes an average of 14 
years from conception to approval and up to 95% of therapeutic drugs fail to make it onto 
the market.46  
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If a therapeutic drug produces adverse reactions or decreased efficiency in animal models 
yet would be more effective in human models, it would be discarded as human trials 
require rigorous testing before they can be attempted. The development of a human 
analogue is far more desirable than the use of animal models in order to understand the 
effects the drugs may have. 
2.7 Biocompatibility issues 
2.7.1 Non-specific defences 
Non-specific biochemical and physical interactions form the primary defence system that 
prevents or hinders foreign material entering the system. There are many non-specific 
defences such as the acidic environment in the stomach, phagocytes in the blood which 
engulf and, remove cellular debris, in addition to intact skin and nasal mucous which 
prevents foreign materials entering the system.   
Also, there are lysozymes in the saliva which can break down bacterial cells before they 
reach the stomach and commensal bacteria in the gastrointestinal tract compete with 
foreign bacteria for space and nutrition. Finally, there is an increased temperature or fever 
which is the system’s final effort to prevent the foreign microbes spreading.  
This increased temperature moves the environment outside the microbe’s optimal 
temperature range but may cause damage to the system and if not controlled can lead to 
death. 
2.7.2 Inflammatory response 
The inflammatory response is of particular concern when administering drugs 
subcutaneously as the response is designed to be triggered by foreign material in the 
system. The subsequent swelling and tissue damage makes certain materials unusable in 
delivery systems. 
The inflammatory response is triggered by the Pattern Recognition Receptors (PRRs) on 
specific cellular components such as macrophages and mast cells. These receptors are 
triggered by cellular damage called Damage Associated Molecular Patterns (DAMPs) or 
invading microbes called Pathogen Associated Molecular Patterns (PAMPs). Ideally a 
substance used for drug administration will cause limited cellular damage reducing the 
amount of DAMPs produced and increasing the strength of the immune response. 
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Once the PRRs are triggered they attract various forms of leukocytes. These include 
neutrophils which are responsible for initiation and maintenance of the inflammation 
response and phagocytes which engulf foreign pathogens forming a phagosome. 
Phagosomes can merge with lysosomes triggering degradation of the engulfed pathogen 
through the release of oxidative species.  
2.8 Industrial applications of nanocellulose and bionanocellulose 
In recent years, there has been a drive towards producing renewable and environmentally 
friendly materials in the pharmaceutical industry. This has led to increased attention for 
materials traditionally considered impractical due to availability, cost or time 
requirements. One of the materials now receiving considerable attention is nanocellulose, 
specifically bionanocellulose which has been used in a variety of medical applications. 
2.8.1 Nanoskin 
Nanoskin is the term for an emerging treatment for chronic wounds and burns. Nanoskin 
utilises bionanocellulose to produce membranes for tissue scaffolding. It promotes 
autolytic debridement which is the painless removal of necrotic tissue via enzymatic 
degradation, reduction of pain and acceleration of granulation where lumpy tissue 
containing connective tissue and capillaries form. These are all important factors for the 
promotion of healthy and rapid wound healing.5 
The main wounds that Nanoskin has been 
used to repair include lacerations or foot 
ulcers caused by diabetes mellitus and 
burned tissue. Traditionally  these chronic 
wounds disrupt the normal wound healing 
process such as reduced production of 
growth factors, collagen accumulation and 
inhibiting granulation.47 
 Other wounds include burns where the epidermal and dermal skin layers have been 
severely damaged, compromising the integrity of the dermal barrier. When the barrier is 
compromised there is a very high risk of bacterial infection. The Nanoskin increases the 
rate of wound healing by providing a scaffold for tissue growth and allowing the passage 
or imbedding of antibiotic agents within its porous material. This prevents infection of 
the wound while also reducing scar tissue formation (Fig 16). 
Figure 16: Wound treated with Nanoskin for 19 days.5 
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2.8.2 Bone repair 
Degradation and loss of bone structure caused by trauma, reconstructive surgery or 
congenital defects present considerable problems for the medical industry. Nanocellulose 
composites have already been shown to aid cellular growth for chronic wounds and the 
aim is to apply this theory to bone repair. 
Current research into bone repair is primarily focused on proof of concept with few 
animal trials conducted. One of the in vivo animal tests did however show promising 
results. The promotion in bone growth involved growth of osteoblast cells, high levels of 
alkaline phosphatase activity and increased bone nodule formation.48 
2.8.3 Nanocellulose drug delivery systems 
Cellulose has been used traditionally as an excipient in order to condense drug loaded 
matrices making oral administration possible as it is non-digestible in the human digestive 
system. It is also not swollen to a dramatic extent within the digestive tract and possesses 
strong binding properties allowing it to be attached to rapidly dissolving active drug 
compounds.49  
Currently there is ongoing research into micro and nanofibrillated cellulose which possess 
a higher purity and can be altered to change the binding characteristics. These factors 
make cellulose applicable for use as oral tablet excipients or a prolonged drug release 
system.48 The swelling nature is also altered from the traditional cellulose excipient, for 
example CNCs are capable of swelling and have been used for uptake and delivery of 
water soluble antibiotics such as tetracycline.  
The nanocellulose can also be used as a co-stabiliser with other excipients such as acrylic 
beads to improve physiochemical and flow properties. An example is the binding of CNC 
which improved the size and size distribution of the beads forming a stable structure with 
a low flow time. Another use is for spray drying treatment on tablets with CNF, enabling 
packing with lower powder porosity and increased mechanical properties.48 
2.8.4 Soft contact lenses 
A hydrogel composed of poly(vinyl alcohol), a water soluble synthetic polymer, is used 
to produce soft contact lens that have a higher tensile strength and absorb fewer proteins 
from the eye than the traditional poly(2-hydroxyethyl methacrylate) lenses.50  
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This creates a lens that causes less irritation to the eye and is less prone to damage, 
increasing the lifespan of the lens. 
2.9 Non-medical industrial applications of hydrogels 
2.9.1 Disposable nappies 
Another commercial use of hydrogels focuses on the ability to absorb water rapidly and 
to retain large volumes of fluid. The production of a low-cost material that is highly 
absorbent and biodegradable made hydrogels composites ideal to be integrated with 
traditional fibres for use in nappies.  
The fibres increased the absorption rate of fluid into the hydrogel with the hydrogel 
swelling and entrapping the fluid for ease of disposal. 
2.10 Cellulose harvesting 
Cellulose harvesting from hemp is done by separating the rough outer fibres from the 
hurd. The hurd is the cellulose core which contains a higher amount of the high quality 
cellulose material desired for nanocellulose production. This can be done through two 
separate processes, decortication or retting. 
The traditional technique used to separate the rough fibres from the hurd is known as 
retting. Retting can be done as dry retting or wet retting. Wet retting is far more water 
intensive but produces higher quality hurd. Dry wetting relies on natural dew fall and 
produces lower quality hurd.51  
The wet retting process involves submerging bundles of the hemp stalks in either still or 
slow-moving water sources such as creeks, ponds or within large vats. The water 
permeates the hemp stalks, making the inner plant cells swell, this applies pressure to the 
outer cells which causes them to rupture. The damaged outer fibres then become more 
susceptible to bacteria which are capable of degrading the cells. This damage makes the 
outer fibres easier to remove mechanically. 
The dry retting process requires high dew fall, the stalks are bundled together and left 
exposed to the elements. Bacteria then degrade the stem material which surround the fibre 
bundles via fermentation. After retting the stalks are dried and then the woody part of the 
stem is broken mechanically and removed leaving the desired hurd.  
28 
2.11 Analytical techniques 
2.11.1 Liquid chromatography 
Liquid chromatography is a separation technique which has been used in a wide range of 
academic and industrial chemical practices. Its primary purpose is to separate components 
within a complex mixture, so that the components can then be analysed or extracted as 
the purified form. The separation is a result of interactions between the mixture, mobile 
and solid phase which determines the type of separation achieved.  
The most common method is liquid-solid chromatography which has the mixture present 
in the mobile phase passing over a solid phase which binds to the compounds resulting in 
the desired separation.  
The separation is dictated by the polarity of the mixture and the phases; this results in the 
various compounds migrating through the solid phase column at different rates. Each with 
its own retention time on the column.52 
2.11.2 Normal and reverse phase chromatography 
Normal phase chromatography involves a mobile phase which is less polar than the solid 
phase (column), the components present in the mixture contain varying polarities and will 
therefore elute at different rates. This technique works most efficiently for non-polar 
compounds, the polar compounds in the mixture are attracted to the polar solid phase so 
have higher retention times. Non-polar molecules which have lower retention rates can 
then be eluted and analysed faster.  
This requires less time, making it easier to analyse multiple samples within the same time 
period while also reducing the amount of mobile phase required. 
Reverse phase chromatography is a similar form of chromatography that involves a solid 
phase (column) which is less polar than the mobile phase allowing separation of the more 
polar molecules with decreased retention times 
2.11.3 High performance liquid chromatography (HPLC) 
HPLC is a separation method based on the principles of liquid chromatography and can 
use normal or reverse phase columns but it also uses a high-pressure system to enhance 
the separation of molecules for collection and then analysis of the compounds using an 
ultraviolet or fluorescence detector.53  
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The separation is achieved by a liquid solvent being passed through an absorbent solid 
phase which separates the individual components based upon their retention times for 
collection, identification or quantitation.  
2.12 Project Aims 
The literature review has shown that there are currently problems with the traditional drug 
delivery systems used for avian analgesia. While butorphanol is an effective analgesic, it 
is rapidly degraded within the body and only produces an analgesic effect for a limited 
time when intravenously injected. Higher dosages of butorphanol also have a chance to 
cause detrimental side effects which are not acceptable. The alternatives such as osmotic 
pumps all present alternative problems including surgical requirements and a long-time 
period between administration and the analgesic effect being achieved.  
The literature has also shown that hydrogels presented an interesting avenue of research 
for producing a safe and effective delivery technique, especially when the hydrogel 
incorporates nanocellulose derivatives. These derivatives have been shown to increase 
the structural stability which is necessary for prolonged release.  
This project aims to solve these problems by producing a hydrogel incorporating 
traditional hydrogel materials and nanocellulose derivatives that are then crosslinked 
together. The hydrogel will be capable of taking up analgesic drugs such as butorphanol 
and then releasing the drug at a slow controlled rate. The hydrogels will be examined with 
in-vitro analysis and in-vivo analysis using broiler chickens. 
The in-vitro analysis will involve submerging the butorphanol loaded hydrogel into 
solution and measuring the concentration of butorphanol in the solution over set time 
points. 
The in-vivo analysis will involve administering broiler chickens with the butorphanol 
loaded hydrogel and measuring the butorphanol levels of the serum at set time points. 
Commercial solutions of butorphanol will be administered to broiler chickens with the 
same dosage. The serum samples will then be analysed using HPLC to determine how 
much butorphanol is present in the serum at each time point and then extrapolated to 
reveal the release rate of the hydrogel.  
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3. Methodology
Materials and equipment 
Chemicals: 
Acetone (CH3)2CO, MWt: 58.08 gmol
-1, CAS 67-64-1, Analytical reagent grade ≥99.5%, 
Fischer Scientific UK 
Acetonitrile  CH3CN, MWt 41.05 gmol
-1, 0.786 kgL-1, CAS 75-05-8, HPLC analytical 
grade 99.8%, Sigma Aldrich NZ 
Butorphanol tartrate C21H29NO2, MWt 327.473, CAS 42408-82-2, Ethical Agents Ltd 
Calcium carbonate CaCO3, MWt 100.0869 gmol
-1, CAS 474-34-1, BDH Chemical Ltd 
Poole England 
Calcium chloride CaCl2, MWt 110.98 gmol
-1, CAS 10043-52-4, AJAX Finechem 
Chitosan 75-85% Deacetylated, CAS 9012-76-4, Sigma-Aldrich NZ 
Disodium hydrogen phosphate dihydrate Na2HPO4.2H2O, MWt 177.99 gmol
-1, CAS 
10028-24-7, BDH Chemical Ltd Poole England 
Glucose C6H12O6, MWt 180.156 gmol
-1, Merck  
Heparin C12H19NO20S3, CAS 9005-49-6, ProVet NZ 
Hydrochloric acid – concentrated Hydrochloric acid: HCl, MWt 36.46 gmol-1, 1.2kgL-
1, 12.18M, CAS 7647-01-0. Sigma-Aldrich NZ.  
Monosodium phosphate NaH2PO4, MWt 119.98 gmol
-1, CAS 7558-80-7, Honeywell 
Riedel-de Haen 
Orthophosphoric acid – concentrated Orthophosphoric acid: H3PO4, MWt 97.994 
gmol-1, 7664-38-2, 14.8, AJAX Finechem 
Sodium alginate (C6H8O6)n (Na)n, extracted from brown algae, low viscosity, CAS 9005-
38-3, Sigma-Aldrich NZ
Sodium bromide NaBr, MWt 102.90 gmol-1, CAS 7647-15-6, BDH Chemical Ltd Poole 
England 
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Sodium chlorite NaClO2, MWt 90.44 gmol
-1, CAS 7758-19-2, technical grade 80%, 
Sigma-Aldrich NZ 
Sodium hydroxide NaOH, MWt 39.997 gmol-1, CAS 1310-73-2 ACS, ISO. Scharlau  
Sodium hypochlorite NaClO, MWt 74.44 gmol-1, 42 gL-1, CAS 7681-52-9, Sigma-
Aldrich, NZ 
TEMPO 2,2,6,6-Tetramethyl-1-piperidinyloxy: 98% C9H18NO, MWt 156.25 gmol
-1, 
CAS 2564-83-2, Sigma-Aldrich NZ 
Equipment: 
22 G catheter - 0.9 x 25 mm, 35 mL/min, BD Insyte 
C18 reverse phase HPLC column Synergi 4µm Fusion – RP 80 Å, LC column 150 x 
4.6mm, P/no OOF-4424-EO 
SPE cartridges Phenomenex Strata-X 33µm, Polymetric Reversed Phase SPE cartridges, 
10 mg/1 mL Phenomenex NZ 
Yeast extract Yeast extract, extracted from autolysed yeast, Baco 
Machinery: 
Centrifuge Eppendorf® Refrigerated Microcentrifuge, Model 5417r 
Freeze drier Non-volatile substances, Model 8891F-MT, John Morris Scientific Ltd 
Homogeniser Model - PowerGen 125, Fischer Scientific 
HPLC UFLC Shimadzu HPLC, Liquid chromatograph LC-20AD, Auto sampler SIL-
20AC HT, Degasser DGU-20A3, Column oven CTO-20A, Diode array detector SPD-
M20A 
Multi-tube vortex SMI multi tube vortex, Model 2601, Scientific Manufacturing 
Industries 
pH meter Mettler Toledo, Model 220 pH Meter 
Sonicator Model 8891F-MT, Cole-Parmer 





Butorphanol standard curve Serial 10 fold 1 mL dilutions of commercial butorphanol 
tartrate (10 mg/mL) with mobile phase to produce 1 µg/mL then serial 2 fold 1 mL 
dilutions with mobile phase to produce 15.6 ng/mL The concentrations used for the 
standard curve were: 1µg/mL, 500 ng/mL, 250 ng/mL, 125 ng/mL, 62.5 ng/mL, 31.2 
ng/mL, 15.6 ng/mL 
GYC Media was prepared in RO H2O, it was composed of 10% w/v glucose, 1% w/v 
yeast extract, 2% w/v CaCO3 with the pH set to 6.8 and autoclaved. 
Hydrochloric acid – diluted 1.015 molL-1 dilute hydrochloric acid solution was prepared 
from 50 mL 12.18 molL-1 stock hydrochloric acid diluted in 550 mL RO H2O.  
Hydrochloric acid - 2M 2.03 molL-1 HCL was prepared from 50 mL 12.18 molL-1 stock 
hydrochloric acid diluted in 250 mL RO H2O 
Mobile phase – pH 4 Mobile phase for RP-HPLC was prepared from 80% phosphate 
buffer and 20% acetonitrile which was then vortexed for 30 s  
Orthophosphoric acid – Diluted 1.06 molL-1 dilute orthophosphoric acid was prepared 
from 50mL 14.8 molL-1 stock orthophosphoric acid diluted in 650 mL RO H2O 
Phosphate buffer Two solutions were prepared to produce the pH 4 phosphate buffer 
(0.1 M). A solution of Na2HPO4 (0.2 M) was prepared from 14.15 g Na2HPO4 salt 
dissolved in 500 mL RO H2O and a solution of NaHPO4 (0.2 M) was prepared from 11.99 
g NaHPO4 salt dissolved in 500 mL RO H2O.  
The phosphate buffer (0.1 M) was then prepared from 187.5 mL of the 0.2 M Na2HPO4 
and 312.5 mL of the 0.2 M NaHPO4 and made up to 1 L with RO H2O in a 1 L Duran 
bottle. The pH was then set to 4 using 1 M ortho-phosphoric acid to lower the pH and 1 
M NaOH solution to raise the solutions pH if overshot. Care was taken to minimise the 
amount of NaOH required, this was done to limit its effect upon the HPLC column. 
Sodium hydroxide – diluted 1 mg/mL NaOH was prepared from 40 g NaOH dissolved 
in 1 L RO H2O 
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3.1 Nanocellulose preparation 
3.1.1 Chemical preparation top down approach 
To remove any waxy components, the initial hemp fibres 
were chemically treated with a 9:1 acetone:water mixture 
over 48 hrs. The mixture was then vacuum filtered, 
washed 4 times with 100 mL aliquots of RO H2O, filtered 
again and dried in a 60oC oven.  
To remove the ligand components, the dried treated fibres 
were stirred in a pH 5 solution composed of 0.6 g 
NaClO2, 1g treated fibres with 32 mL of RO H2O for every 1 g of solid material, the 
temperature was maintained at 70oC.  
The aqueous solution of NaClO2 was replaced every 3 hrs with a fresh solution. The solid 
material was filtered off and then added to a new volume of solution at the same 
temperature.  
After 15 hrs the fibres were then filtered and washed with 100 mL of RO H2O 4 times, 
blended in a commercial blender on high speed, re-filtered and freeze dried. The 
processed fibres produced had a pale yellow/white colour with a soft texture similar to 
cotton fibres (Fig 17). 
3.1.2 Biological preparation 
This preparation strategy focused upon exploiting the 
bacterium G. xylinus in order to produce high quality 
nanocellulose which was required for medical 
purposes.  
The initial colonies of G. xylinus were taken off a GYC 
agar plate, supplied by the Institute of Fundamental 
Sciences, and used to incubate a 10 mL culture of GYC 
media within a test tube with a cotton wool plug.  
The culture was then incubated at 30oC for 48 hrs, during this time it produced a cellulose 
pellicle. The test tube culture was then used to inoculate 200 mL of GYC medium in a 
500 mL Duran bottle and was re-incubated for a further 48 hrs.  
Figure 17: Hemp fibres after NaClO2 treatment. 
Figure 18: Cellulose pellicle produced by G. 
xylinus in GYC media. 
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The culture was then removed and placed into a 2 L Erlenmeyer flask containing 1 L of 
GYC media and re-incubated for 6 weeks where it produced a thick pellicle of 
nanocellulose at the liquid-air interface (Fig 18). This pellicle was then removed (Fig 19), 
and the solution was re-incubated with an additional 200 mL of GYC media allowing for 
the bacterial culture to produce additional cellulose pellicles.  
The pellicle was then placed into falcon tubes with holes 
melted into the lid. The falcon tubes were freeze dried 
for 48 hr to reduce the viability of any microbial 
organism’s present. The pellicle was then removed and 
suspended in a Durnan flask with 200 mL of 1% NaOH 
for 1 hr at room temperature. The flask was then 
submerged in boiling water for 30 min and centrifuged 
at 6000 RPM for 20 min. The pellicle within the flask was then washed with RO H2O and 
centrifuged for another 20 min. The pellicle was then suspended in Cross-Beaver reagent 
(200 mL 1 M HCl with 100 g ZnCl2) for 24 hr to dissolve the cellulose pellicle.  
Four volumes of 95% ethanol were then added to the solution and placed on a shaker at 
room temperature in order to aid the precipitation of the nanocellulose material. The solid 
nanocellulose was then centrifuged at 6000 RPM for 20 min, dissolved in RO H2O and 
placed into dialysis tubing. The tubing was submerged in RO H2O and stirred gently to 
remove any small degraded particles while retaining the nanocellulose.  
Finally, the contents of the dialysis tubing were removed and centrifuged at 2000 RPM 
for 10 min then freeze dried for 24 hr to produce the purified nanocellulose.  
This nanocellulose was then TEMPO oxidised to produce processed bionanocellulose and 
isolated using the same technique provided in 3.1.3. 
Figure 19: Biocellulose pellicle.
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3.1.3 TEMPO 
TEMPO oxidation of the treated fibres was used to prepare the cellulose microfibrils for 
hydrogel formation.  
1 g of pre-TEMPO cellulose microfibrils was stirred in a beaker with 200 mL of RO H2O 
for 1hr. 0.1 g of NaBr with 0.016 g of TEMPO as a catalyst was then added to the beaker; 
the solution was stirred on high for a further 30 min. 
26.5 mL sodium hypochlorite solution was then added and the solution continued to be 
stirred until the reaction had completed. This reaction required the solution to be 
maintained at pH 10 with dilute sodium hydroxide and dilute hydrochloric acid used to 
alter the pH. When the pH change was less than 0.2 over the course of 1 hr, the reaction 
was completed (≈ 12 hr). After the reaction was completed, it was quenched with 1 mL 
of ethanol and the pH was set to 7.  
The solution was then filtered and the solid product was 
washed four times with RO H2O. The fibres produced were 
colourless with a gel like texture. This material was then 
placed into the freeze drier overnight, producing a soft white 
solid (Fig 20).54  
3.2 Hydrogel preparation 
3.2.1 Sodium alginate mixed hydrogels 
For this study 0.27 g sodium alginate was mixed with 0.03 g TEMPO oxidised 
nanocellulose at a ratio of 1:9 with 30 mL of 10 mg/mL butorphanol to form a 1 m/V% 
hydrogel. Negative controls of pure sodium alginate and TEMPO oxidised nanocellulose 
were also produced. The solutions were then homogenised.  
3.2.2 Chitosan mixed hydrogels 
Chitosan hydrogels were prepared following the same method detailed in 3.2.1 with high 
quality NaOH treated chitin replacing the sodium alginate. 
3.2.3 Dry NC-SA hydrogel swelling and release patterns 
To determine the swelling rates for dry hydrogels, combinations of TEMPO oxidised 
nanocellulose and sodium alginate at ratios of 1:0, 1:9, 1:1, 9:1 and 0:1 were prepared in 
20 mL of RO H2O. The nanocellulose was suspended in 10 mL RO H2O and sonicated 
for 1 hr, the sodium alginate was dissolved in 10 mL RO H2O and stirred for 2 hr.  
Figure 20: Purified nanocellulose. 
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The nanocellulose was then added to the sodium alginate, stirred for an additional hour 
then homogenised for 5 min to produce a viscous solution. The solution were then poured 
into a petri dish, placed in a 60oC oven for 24 hr and then freeze dried for 24 hr to produce 
a dried hydrogel.  
This was repeated for all of the NC:SA ratios. 
The hydrogel was then suspended in 20 mL of a 5% solution of CaCl2 for 24 hr according 
to previous studies conducted with sodium alginate hydrogels55, oven dried at 60oC for 
24 hr and freeze dried for 24 hr to produce the final dried hydrogel.  
The dried hydrogel masses were measured and then placed into a beaker of 200 mL RO 
H2O to re-hydrate and swell the hydrogels, in order to determine the water absorption 
rate. After the hydrogels had been incubated for 30 min, the hydrogels were removed and 
placed on filter paper briefly to remove peripheral water then weighed to determine the 





WA is the water absorption rate, Mw and Md are the wet and dry masses respectively. 
The swollen hydrogels were then centrifuged for 3 min at 3500 RPM to determine the 





WR is the water retention rate, Mh and Md are the masses after centrifugation and initial 




3.2.4 NC-SA hydrogel gel preparation 
3.2.4.1 Preparation of hydrogel for animal testing 
Nanocellulose and sodium alginate hydrogels were prepared for animal testing from the 
nanocellulose prepared in 3.1.3 and sodium alginate. 0.03 g of the nanocellulose was 
placed into 15 mL of RO H2O and sonicated for 1 hr to begin breaking down and 
dissipating the nanocellulose clumps. 0.27 g of sodium alginate was then stirred in 15 mL 
of RO H2O for 2 hr until it had completely dissolved.  
The solutions were then combined and stirred for a further 2 hrs, then the solution was 
homogenised for 5 min to form a uniform clear viscous solution. This solution was then 
poured into a sterile petri dish and freeze dried for 24 hr. 
The freeze dried gel was then re-suspended in 30 mL of 1% CaCl2 solution to facilitate 
ionic crosslinking and increase the stability of the gel. This solution was stirred for 6 hrs 
and then homogenised for 5 min to produce a more viscous yet still clear solution as seen 
in the previous step. The solution was poured into a sterile petri dish and freeze dried for 
a further 24 hr. 
The dried gel was then re-suspended in 30 mL of 10mg/mL butorphanol, stirred for 6 hrs, 
homogenised for 5 min and then stirred for 12 h to ensure the drug had loaded onto and 
into the hydrogel. This 30 mL of hydrogel was then used for the animal testing. 
All stirring steps occurred at 4oC in a sterile environment to reduce the risk of microbial 
contamination and degradation of the hydrogel. 
3.2.4.2 Preparation NC-SA hydrogels for drug release in RO H2O 
To prepare the NC-SA hydrogels, 0.03 g of nanocellulose, prepared using the method 
detailed in 3.1.3 was suspended in 15 mL of RO H2O and sonicated for 1 hr. 0.27 g of 
sodium alginate was suspended in 15 mL RO H2O and stirred at high speed for 2 hr. The 
nanocellulose and sodium alginate solutions were then combined, stirred on high for 1 hr 
and then homogenised for 5 min. The solution was then poured into a sterile petri dish 
and freeze dried for 24 hr. 
The freeze dried solution was then re-suspended in 30 mL of a CaCl2 solution. This 
solution was stirred on high for 6 hrs and then homogenised for 5 min. The solution was 
poured into a sterile petri dish and freeze dried for 24 hr. 
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The dried gel was then re-suspended in 30 mL 10 mg/mL butorphanol, stirred for 6 hrs, 
homogenised for 5 min and then stirred for 12 hr. The concentration of CaCl2 solutions 
used were 0.5 molL-1, 1 molL-1, 1.5 molL-1. 
3.2.4.3 Preparation of chitosan-SA hydrogels for drug release in RO H2O 
This preparation was done identically to 3.2.4.2 with the following alterations. Sodium 
alginate was replaced with chitosan and the CaCl2 concentration was set at 1 mg/mL. 
3.2.5 Hydrogel drug release in RO H2O 
The prepared hydrogels were taken from the freeze drier and placed into 200 mL beakers. 
100 mL of room temperature RO H2O was gentle poured into the beaker with care taken 
to prevent disruption of the gel film. 
A small stirrer bar was placed into the beaker and stirring commenced at a low speed 
(setting 1) 
The gel film would float to the top of the vessel for 2-3 min before absorbing enough 
liquid to allow it to settle onto the bottom as a distinct layer roughly 2-3 cm thick.  
At 15 min a 1 mL sample was taken from the water layer (1cm below surface air interface) 
and 1 mL of fresh RO H2O was added to maintain the volume of the vessel at 100 mL.  
This was repeated at time intervals of 30 min, 1, 2, 4, 6, 12, 24 hrs. 
These samples were then centrifuged at 13,000 RPM for 2 min and analysed using the 
using HPLC following the methods detailed in 3.4.3 and 3.4.4. 
3.3 Avian testing 
3.3.1 Animal trials 
The animal trials were conducted by Dr Preet Singh, School of Veterinary Sciences, 
Massey University. The protocol for this experiment was approved by the Massey 
University ethics committee.  
The pilot trial used six broiler chickens with an average live weight of 2 kg. 
The primary study involved 16 broiler chickens with an average live weight of 3.5-4.5 
kg. This study had six chickens injected with the nanocellulose-alginate hydrogel 
(treatment group) described in 3.2.4 and six chickens injected with commercial 
formulation of butorphanol (control group).  
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Four of the chickens were kept for blank plasma collection and to be used as replacements 
if any of the other chickens died or could not have catheters inserted due to damaged 
veins or uncooperative nature.  
Each chicken was catheterised with a 22 G catheter into the medial metatarsal vein after 
gentle restraining of the bird. The catheters were firmly fixed by wrapping the 
catheterised leg with cohesive bandage. The patency of the catheters were maintained by 
flushing with 0.5 mL 10% heparin- solution.  
The chickens were kept under standard conditions and were fed ab lib with commercially 
available chicken feed and a 24 hr supply of fresh drinking water was made available. 
The catheters had heparin inserted to prevent coagulation and clotting of blood within the 
catheter.  
3.3.2 Drug administration 
The control group chicken received Butorphanol tartrate 10mg/mL (Butorphic Injection; 
Llyod Laboratories) at 6 mg/kg dose, subcutaneously using a 22G needle at midline 
caudo-dorsal region of the neck. The treatment group chickens received nanocellulose 
alginate formulation of butorphanol subcutaneously at a similar dose (Table 2) and site 
of injection as the control group. 
3.3.3 Serum collection 
The broiler chickens from the pilot study had 1 mL and the chickens from the primary 













1 3.3 2.0 1 4.1 2.5 
2 3.5 2.1 2 4.2 2.5 
3 3.7 2.2 3 4.0 2.4 
4 3.8 2.3 4 4.3 2.6 
5 3.9 2.3 5 4.1 2.5 
6 3.6 2.2 6 3.9 2.3 
Table 2: Primary study. Chicken number with associated weight and volume of 10 mg/ml hydrogel / butorphanol injected. 
6 mg/mL dosage. Chicken G were injected with the NC:SA hydrogel formulation. Chicken NG were injected with 
commercial 10 mg/mL butorphanol.  
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The samples were collected at 0, 15, 30, 60 minutes and 4, 8, 16 and 24 hrs after injections 
of commercial butorphanol and 0, 15, 60 minutes and 2, 4, 8, 16, 24, 32, 48, 72 and 96 hr 
after injections of the hydrogels loaded with butorphanol (Appendix i,ii). 
After collection, the blood samples were placed into an ice bath to cool then centrifuged 
for 10 min at 2000 RPM to separate unwanted materials from the plasma containing the 
butorphanol. The plasma samples were then isolated and placed into a -70oC freezer for 
storage. 
3.4 Sample preparation 
3.4.1 HPLC analysis preparation 
The chicken plasma samples were stored at -70oC, the samples were defrosted at room 
temperature in water to speed up the defrosting process. 300 µL of the chicken plasma 
sample was then removed for testing and the remaining sample was immediately returned 
to the -70oC freezer for further analysis if required. Some samples were frozen then 
defrosted multiple times and there was no adverse effect upon the HPLC results observed 
when compared to the initially defrosted samples results. 
300 µL of chicken plasma was diluted with 300 µL of RO H2O and vortexed for two 
minutes to ensure even distribution of the plasma within the solution. 300 µL of 2 M HCl 
was then added to the sample and vortexed to maximise the exposure of the blood plasma 
to the acid. The solution was then centrifuged at 13,000 RPM for ten minutes to sediment 
the unwanted particles, separating them from the desired supernatant for SPE loading. 
3.4.2 Solid phase extraction 
Phenomenex Strata-X 30 mg/1 mL Polymetric Reversed Phase SPE cartridges were 
preconditioned with 1 mL of 100% methanol and then equilibrated 1 mL of RO H2O 
while under vacuum filtration. The supernatant from the samples was then loaded into the 
pre-conditioned SPE cartridge and run under vacuum filtration until dry.  
After the serum was loaded, the SPE tubes were washed with 1 mL of RO H2O, run until 
dry and then left under vacuum for a further two minutes. An additional wash of 1 mL 
40% methanol was then added and left under vacuum suction for a further two min. A 1 
mL sample of 100% methanol was then added to elute the butorphanol from the SPE 
cartridge where it was collected into 5 mL test tubes.  
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These tubes were then dried under reduced pressure at 20oC with centrifugation at 13,000 
RPM for 10 min. The sample was then reconstituted in 200 µL of the mobile phase (2:8 
acetonitrile: 0.1 M phosphate buffer pH 4), placed into HPLC vials containing inserts to 
reduce the risk of needle tracking errors and placed into the HPLC loading rack which 
was kept at 4oC. 
3.4.3 HPLC preparation protocol 
The two feed lines were placed into Duran bottles containing 0.1 M pH 4 phosphate buffer 
and 100% acetonitrile respectively with aluminium foil sealing the lid, then the valves 
were opened bypassing the HPLC column and the system was purged to remove any air 
bubbles present in the lines which could cause problems with the HPLC. The acetonitrile 
had already been placed in a sonicator on degassing setting for 10 minutes to remove any 
bubbles present.  
After the system had purged the valves were closed and the 80% gradient of 0.1 M pH 4 
phosphate buffer to 100% acetonitrile was run at a flow rate of 0.2 ml/min for 2 min, it 
was then increased by 0.2 ml/min every 2 min until it reached the desired flow rate of 
1ml/min. It was then run at this rate for 30 min before the HPLC run was begun to ensure 
any contaminant in the column that had not been removed by the cleaning protocol would 
have been removed and the HPLC column would have a uniform surface. 
3.4.4 HPLC run protocol 
Sample injection volumes of 50 µL were done in duplicate with the samples cooled to 
4oC and the column set at 40oC. There was a run time of 15 min under isocratic conditions 
with a binary gradient of 80% phosphate buffer with 20% acetonitrile and a flow rate of 
1 mL/min to separate the butorphanol peak from other peaks present in the solution.  
The UV absorption was measured from 200-280 nm, the peaks that were observed when 
the absorption was at 202 nm were used to calculate the butorphanol concentration. 
3.4.5 HPLC cleaning protocol 
The system was cleaned after every sample set had been run to avoid contamination of 
sequential samples and pressure increases due to clogging of the guard column and HPLC 
column by precipitation of the salts in the buffer  
This cleaning involved placing the feed lines into a Duran bottle containing RO H2O and 
purging the system with the same method detailed in 3.4.3.  
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After purging the valves were closed and the HPLC column was removed and placed 
aside. Both feedlines then had their flow rates set to 2.5 mL/min and run for 5 min The 
pumps were then tuned off, the HPLC column was reattached, the flow rates were set to 
0.2 mL/min and the pumps turned on again for 30 min.  
The pumps were then turned off and the feedlines were placed into Duran flasks 
containing a solution of 50:50 acetonitrile:RO H2O. The system was purged following 
the same procedure then run at a 0.2 mL/min flow rate for each feedline for 30 min 
3.5 HPLC Validity 
3.5.1Butorphanol recovery 
To determine the recovery rate of butorphanol from SPE cartridges, blank serum samples 
were spiked with 300 µL of each known concentration used in the butorphanol standard 
curve. The butorphanol solutions replace the RO H2O step of solid phase extraction. The 
HPLC run protocol remains unchanged. 
The spiked plasma samples were run in triplicate with the peak area, height and retention 
time compared to the results from the butorphanol standard curve.  
This was done to determine the recovery rate of butorphanol after SPE. 
3.5.2 HPLC specificity 
Blank plasma from 16 broiler chickens was extracted from blood samples and analysed 
using HPLC after SPE to determine the specificity of the method. 
3.5.3 HPLC analysis 
Standard curves were constructed using the butorphanol standard curve at the beginning 
the alternating plasma samples and butorphanol standard curve. These samples were run 
in duplicate using the HPLC run protocol. 
3.5.4 Chromatograph analysis 
The chromatograph readings for the butorphanol standard curve and plasma samples were 
analysed for peak area, height and retention time. The concentration of butorphanol 
contained within the plasma samples was then calculated by comparing the peak results 
to a calibration curve produced by the butorphanol standard curve. This was all calculated 
using LC solution software with manual integration used for peaks with a height below 
200 or areas below 500. 
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3.5.5 New Column 
A standard curve of butorphanol standards in mobile phase from 1 µg/mL, 500 ng/mL, 
250 ng/mL, 125 ng/mL, 62.5 ng/mL, 31.2 ng/mL and 15.6 ng/mL was run on the new 
column in triplicate with the same protocol as 3.4.4. The chromatograph was then 
analysed to determine the maximum and minimum concentration that could be accurately 
determined.  
3.5.6 HPLC Linearity 
This butorphanol standard curve was run in triplicate using the same HPLC technique 
used for the HPLC run protocol. This data obtained was then analysed and subjugated to 
linear regression in LC solution software to determine if there was any variation in 
intraday samples. 
3.6 Data analysis 
Variance is calculated for the butorphanol standard curve, the HPLC chromatograph area 
and height data and averages.  
The formula is: 
𝑉𝑎𝑟𝑖𝑎𝑛𝑐𝑒 = 𝑉𝐴𝑅. 𝑃(𝑥1: 𝑥𝑛)/𝐴𝑉𝐸𝑅𝐴𝐺𝐸(𝑥1: 𝑥𝑛) 
x1 = initial value, xn = final value 
This is then used to calculate the percentage variance: 
%𝑉 = 100 − ((𝐴/(𝐴 + 𝑉)) ∗ 100) 
A = Average area/height, V = Area/height variance 
The concentration is then calculated from the butorphanol standard curve results which 
produce a linear line of best fit. The formulae of the line are then used to determine the 
concentration of the samples based upon area and height. 
The RO H2O hydrogel release study required an additional calculation to negate the effect 
of removing 1 mL samples and replacing with 1 mL fresh RO H2O.  
𝐴𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝑐𝑜𝑛𝑐 = 𝑐𝑜𝑛𝑐 ∗ (
100
(100 + (𝑛 − 1))
) 





The results were the graphed with the concentration calculated using the average areas vs 
time and the concentration calculated using the average heights vs time. 
The original 300 µL of chicken serum sample were reduced to a 200 µL final volume. 
The calculated concentration of the sample was adjusted to take into account this 




) = (𝑂𝑟𝑖𝑔𝑖𝑜𝑛𝑎𝑙 𝑐𝑜𝑛𝑐 (
𝑛𝑔
𝑚𝐿
) ∗ 0.2)/0.3 
3.6.1 Statistical analysis 
The pharmacokinetic parameters from three different groups calculated by the methods 
described above were compared by one-way ANOVA non-parametric using Prism 6 for 
Macintosh (GraphPad Software, Inc, CA, USA). The multiple comparisons were made 
by Kruskal-Wallis test. Significance was set at p < 0.05. 
3.6.2 Pharmacokinetic analysis 
Pharmacokinetic parameters were determined using noncompartmental analysis. 
PKSolver ‘add-on’ for Excel 201056 was used to calculate pharmacokinetic parameters 
using individual plasma concentration data. 
(6)
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4. Results and discussion
4.1 Pre-TEMPO chemical preparation 
In addition to the desired cellulose, the raw stock hemp fibres contained numerous 
compounds which needed to be removed before the cellulose could be extracted and 
processed. The initial steps removed the fatty lipids from the hemp fibre surface using an 
acetone:water solution followed by separation of the pectin, lignin and other chemical 
components such as tannins and hemi-cellulose from the desired cellulose. This was done 
according to the modified Wise method detailed in 3.1.1.  
The multiple washes with RO H2O after acetone:water treatment ensured the removal of 
any remaining water soluble impurities. The sample was then dried to remove the 
remaining water and acetone. This was done to prevent it interfering with the NaClO2
solution. Any water present would have changed the weight of the hemp fibres which 
would have altered the hemp weight to volume NaClO2 ratio used, potentially changing 
the degree of ligand removal.  
The modified Wise method was performed at 70oC to increase the rate of reaction 
between NaClO2 and any ligand compounds while also causing heat degradation of the 
hemp structure. This reduced the structural integrity of the hemp fibres and increased the 
permeability, allowing the NaClO2 to penetrate further and remove a higher percentage 
of the ligands present.  
The NaClO2 was added to remove any lipids present in the solution. It was done in 
multiple washes to ensure that there was fresh NaClO2 to act upon any remaining lipids 
after the heat had begun to degrade the fibres over time. The longer run times than the 
original Wise method allowed the fibres to form a much finer white solid which had a 
larger exposed surface area for TEMPO oxidation. This also increased the amount of 
fibres that formed nano-fibrils instead of micro-fibrils which were preferable for hydrogel 
formation. 
The final steps involving the commercial blender were to maximise the mechanical 
breakdown of the fibres before TEMPO oxidation. This increased the surface area of 
hemp fibre available for the TEMPO reaction to affect and produced higher quality 
cellulose microfibrils. The material loss from the transfer between the blender and beakers 
was considered to be an acceptable loss. 
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4.2 Bionanocellulose preparation 
The initial cultures of G. xylinus were taken from frozen glucose stocks, they were known 
to still be viable and were believed to be capable of producing the levels of cellulose 
desired.  These cultures were then plated out onto GYC agar that was capable of growing 
the microbe to the desired levels at the ideal growth temperature of 30oC without 
excessive treatment being required.  This ensured that there were enough colonies 
available for incubation in the GYC media without contaminants.  
The cultures required access to oxygen and the prevention of airborne microbes from 
contaminating the sample. To solve these problems, a cotton wool plug was placed into 
the neck of the flasks and was considered to be a suitable solution as a microbe filter. 
The three stages of upscaling for the liquid media chosen were a 10 mL test tube, a 250 
mL Duran flask and 2 L Erlenmeyer flasks. 
The test tube had a low surface area to volume ratio so was not suitable for large scale 
production. The pellicle formed on the liquid air interface. This decreased the oxygen 
content of the solution which is required by the aerobic G. xylinus. However, it did allow 
for the growth of the microbe to be easily identified as well as determining if there was 
any contamination by other microorganisms without wasting large volumes of GYC 
media.  
The 250 mL Duran flask had a greater surface area to volume ratio but lacked the required 
surface area and nutrient levels for production of larger pellicles. It was however, a very 
useful step in the scale up process. It provided a final check to ensure that there was no 
contamination present before the final upscaling step which had the largest GYC media 
requirement.  
The 2 L Erlenmeyer flask proved to be the most suitable for large scale production. It 
produced a thick pellicle which could be harvested. The culture could then be re-
incubated to produce multiple pellicles provided the solution was not contaminated by 
other microbes and that there were suitable levels of oxygen and nutrients present in the 
solution. This however proved to have diminishing returns with smaller pellicle sizes and 
repeated harvesting dramatically increased the risk of contamination. Even when 
conducted under aseptic conditions, the non-specific nature of the media allowed fungal 
colonies to grow rapidly if exposed to the solution.  
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Maintaining a sterile environment when working on the cultures proved difficult due to 
the large volumes and multiple transfers leading to fungal contamination of one of the 
cultures. This only became prevalent in one culture when the 2 L flask was re-incubated 
after removal of the cellulose pellicle. In one preparation, the fungal contamination 
resulted in a disrupted and mechanically weaker cellulose pellicle thought to be due to 
either competition for nutrients or an antibiotic effect caused by the fungal species causing 
bacterial cell death. This pellicle was degraded during isolation so was therefore unusable. 
The initial bionanocellulose pellicles produced had an average freeze-dried weight of 0.8 
g after 3 weeks incubation. The processed weight however was only 0.12 g and with the 
normal 54% yield loss due to TEMPO oxidation demonstrated by the hemp nanocellulose 
it was decided not to continue with the TEMPO oxidation.  
The experiment was re-attempted with a 6-week incubation time for the 2 L Erlenmeyer 
flask step. This produced a much thicker pellicle with a stronger binding. The freeze-
dried weight was 2.1 g but after further processing the final weight came to 0.74 g. This 
was then treated with TEMPO oxidation in the same manner as the hemp fibres in 3.1.3. 
The final weight came to 0.25 g but this was deemed to be insufficient for production of 
hydrogels. 
Subsequent growth attempts lead to similar results believed to be a result of the colony 
strain not being suitable for large scale bionanocellulose extraction. This preparation was 
therefore discarded in favour of the top-down nanocellulose extraction from hemp fibres 
which had a far lower time requirement. Larger quantities of the initial raw material were 
available. This methadology was capable of producing usable amounts of nanocellulose 
for hydrogel production. 
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4.3 TEMPO oxidation 
The initial 1 hr stirring step ensured that the cellulose microfibrils were dispersed in the 
solution and any clumps were disrupted. This maximised the surface area exposed to the 
solution. This was done to maximise the reaction rate and permeation. This increased the 
proportion of nanocellulose produced from the microcellulose for hydrogel formation. 
TEMPO is a stable nitroxyl radical with many applications in organic chemical and 
biochemical processes57. For one of the primary chemical processes, TEMPO is used as 
a catalyst in the presence of NaBr to cause the conversion of pseudo amorphous cellulose 
into the polyglucuronic acid sodium salt with NaOCl as the catalytic reagent (Fig 21). 
Maintenance of pH 10 is required to reduce the degradation of the polymer chains and 
the accumulation of unwanted side products which would reduce the amount of usable 
nanocellulose for hydrogel formation. 
After freeze drying, the processed samples gave an average percentage yield of 46% 
(Table 3). The decreased percentage yield is believed to have been a result of the TEMPO 
oxidation breaking down some of the cellulose polymer chains to produce short chain 
molecules which could not be recovered. There were also transfer losses when the 
processed nanocellulose was extracted via vacuum filtration as the colourless gel was 
difficult to observe and formed films upon the sides of the filter as well as the filter itself 
preventing recovery without contamination with fibres from the filter.  
Figure 21: TEMPO oxidation of cellulose.8 
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Modification of the cellulose chains allowed formation of multiple C6 carboxylate groups 
which assisted in the formation of strong hydrogels from mixed preparations. This occurs 
because of the interactions between the post TEMPO nanocellulose and other compounds 








(g) % Yield 
1 1.01 0.48 0.53 47.5 
2 1.03 0.50 0.53 48.5 
3 0.98 0.44 0.54 44.9 
4 1.00 0.45 0.55 45.0 
5 1.04 0.49 0.55 47.1 
6 1.06 0.49 0.57 46.2 
7 0.99 0.44 0.55 44.4 
Average 1.02 0.47 0.55 46.3 
 
 
Figure 22: TEMPO oxidised cellulose (Blue) and sodium alginate (Black) chains crosslinked with CaCl2. 
 
Table 3: Yield from multiple runs of TEMPO oxidation on cellulose fibres. 
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4.4 Nanocellulose optimisation 
Processing of hemp fibres to extract cellulose fibrils with a nanometer dimension uses 
many traditional techniques such as acetone treatment and TEMPO oxidation. Due to the 
coarse nature of the fibres compared to the cotton fibres traditionally used, alterations 
were required to the techniques to optimise the yield. 
The initial removal of lipids from the hemp fibres using an acetone:water mixture had the 
treatment time increased to 48 hr from 24 hr. This made the fibres become soft and white 
with a cotton like texture instead of rough brown woody fragments.  
The NaClO2 shock treatment of the treated hemp fibres was extended from four shocks 
of two hour duration each, to five shocks of three hour duration each. This produced softer 
fibres which had begun to break down. They could then be mechanically degraded further 
using a blender. 
The degraded hemp fibres were more easily oxidised to a greater degree using TEMPO 
than fibres produced using the traditional techniques. 
The TEMPO oxidation technique from 3.1.1 was unchanged from the literature except 
for a two hour extension of the incubation period until the pH change of the solution had 
slowed to less than approximately 0.5 pH/hr. Then the solution was left overnight to 
produce a final average pH reading of 9.4 before it was quenched with ethanol and set to 
pH 7. 
4.5 Hydrogel preparation 
There have been many polysaccharides which have been used to form hydrogels. The two 
most commonly used are sodium alginate extracted from the cell walls of algae and 
chitosan produced from chitin which is extracted from the shells of shellfish. Therefore, 
two polysaccharides were considered for a combination hydrogel preparation with 
nanocellulose. Due to the limited timeframe available for the project, sodium alginate was 
chosen to be combined with nanocellulose fibrils. This was decided as the sodium alginate 
was readily available in high quality and could be crosslinked with nanocellulose. 
Chitosan was briefly examined as a potential hydrogel material as it had similar 
characteristics to sodium alginate. It was also available in acceptable quantities and could 
be crosslinked with nanocellulose using CaCl2. 
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4.5.1 Dry NC-SA hydrogel swelling patterns 
Dry hydrogel water absorption and water retention rates were outside of the expected 
range. Previous sodium alginate studies had shown water absorption and retention rates 
at 10-fold and 5-fold higher levels respectively. This was later decided to be a result of 
the higher strength of the hydrogel matrix. 
The water absorption rates obtained showed consistent rates across the triplicates studied 
but the maximum absorption rate for the 1:9 NC:SA gel had an average rate of 91% 
increase compared to the literature study with 1040%. The maximum water retention rate 
was 85% compared with the 569% from the literature.55  
The other hydrogel compositions had lower absorption and retention rates than the 1:9 
NC:SA ratio hydrogels. It was therefore decided that while the WA and WR rates were 
far lower than expected this provided confirmation that the 1:9 NC:SA ratio was the most 
efficient available.  
The lower rates could be explained by the nature of the nanocellulose. The nanocellulose 
extracted from hemp possessed a far higher mechanical strength then the nanocellulose 
extracted from cotton used in the literature. This resulted in the stronger hydrogel lattice. 
The stronger hydrogel lattice would have restricted the swelling potential and this would 
also have affected the water release rate by restricting the contraction of the hydrogel. 
 The cellulose content of cotton was far higher with an average of 94% while hemp pulp 
has an average cellulose content of 40-45%.9 This meant that the cotton fibres required 
less intense treatment which may have resulted in the hydrogels produced to have a lower 
density, allowing for more water to be taken up into the matrix and retained.  
4.5.2 RO H2O NC-SA hydrogel release  
The concentration of CaCl2 was altered to determine the optimal amount of crosslinking 
required to produce suitable hydrogels. The hydrogel needed to be capable of taking up 
and retaining the drug while maintaining their matrix structure to allow for a prolonged 
release rate. The hydrogel was also required to be viscous enough to allow subcutaneous 





Calcium chloride was chosen as the crosslinking reagent. It produced Ca2+ ions capable 
of forming an ionic bridging bond between two polymer chains and had been commonly 
used in other studies. Other bridging compounds such as magnesium chloride were briefly 
considered but were not investigated due to time restrictions and the efficiency of CaCl2. 
The three concentrations of CaCl2 were chosen to provide a wide concentration range. 
This would produce a hydrogel that would be crosslinked together to form a more viscous 
gel while still being injectable. The lowest concentration CaCl2 produced a very fluid gel 
that had released 90% of the drug into solution within the first hour. This was decided to 
be inadequate as the hydrogel would ideally decrease the drug release rate so it would 
continue to release an effective dose for multiple days.  
After 6 hrs there was depreciation in the drug level detected within the sample from the 
0.5% CaCl2 hydrogel. This is potentially caused by the hydrogel degrading and the 
individual polymer chains binding to the butorphanol in solution, isolating the drug to the 
lower levels of the vessel. The samples were taken from the upper layer and therefore if 
the hydrogel components bound the butorphanol, some of the butorphanol would sink to 
the bottom of the beaker would be unavailable, decreasing the overall concentration of 
the solution.  
The samples were taken from the top of the vessel to prevent uptake of any hydrogel that 
could alter the samples concentration after processing. The samples were centrifuged to 
remove any solid components that may produce blockages within the HPLC or corrupt 
the results.  
This may cause any hydrogel components that were taken up in the sample to release the 
encapsulated butorphanol. This would cause a spike in the butorphanol concentration of 
the sample (Graph 3), artificially increasing the calculated release rate (Table 5). 
 This is likely why there was a large spike in butorphanol concentration at the 30 min 
sample for the 0.5% CaCl2 gel (Graph 3). The gel had not settled completely at the base 
of the vessel and the structural rigidity of the gel was the weakest due to the lowest amount 
of crosslinking present. This may have caused some hydrogel to be present in the sample 




The 1% CaCl2 gel exhibited the best release rate of the butorphanol, it had the slowest 
release rate observed and the concentration of butorphanol in the solution remained 
relatively constant after 6 hrs. This is likely due to the structural rigidity of the gel 
allowing uptake of the butorphanol while also being capable of tolerating the agitation 
caused by the stirrer bar without disrupting the hydrogel matrix. 
The 1.5% CaCl2 gel showed the most rapid drug release rate. The majority of the drug 
had been released within the first hour. This was not desirable as the aim was to produce 
a long-term release gel. The rapid release rate was believed to be a result of the 
crosslinked hydrogel preventing uptake of the butorphanol into the gel. Instead the drug 
was mostly confined to the peripheries of the gel. When the gel was submerged in RO 
H2O the bonds connecting the butorphanol to the hydrogel peripheries were disrupted 
resulting in a large amount of free butorphanol in the solution. 
The 1% CaCl2 gel was considered to be the ideal balance between a robust hydrogel 
capable of surviving longer periods in solution without physical changes. It also formed 
a hydrogel with a density capable of taking up butorphanol into the matrix, lowering the 
drug release rate. 
The 1% CaCl2 was chosen as the most appropriate gel for the animal trials and therefore 
studies proceeded with a 3% m/V 1:9 NC-SA 1% CaCl2 gel. 
4.5.2 Wet NC-SA hydrogel preparation 
4.5.2.1 Pilot study  
The hydrogels were initially prepared with a 1 m/V% 1:9 NC:SA composition. This was 
due to the processed nanocellulose being scarcer, more expensive than the sodium 
alginate and based on the results obtained in 4.5.1. In order to produce a larger number of 
replicable gels, the lower NC:SA ratio was used with further release studies planned with 
the higher NC:SA ratios to determine an optimal ratio to balance efficiency and cost. 
The other consideration was the viscosity of the hydrogel, the administration into the 
chicken involved a subcutaneous injection. This made highly viscous gels with large scale 
crosslinking impractical. The 1% m/V 1:9 NC:SA gel with 1 mL of 1% CaCl2 had at that 
stage of the project, the highest viscosity while still being capable of being delivered via 
injection to the broiler chickens.  
54 
 
This was later improved with modifications to the processing steps for nanocellulose 
producing hydrogels that had limited clumping at higher concentration hydrogels. 
The butorphanol concentration in the gels was 10 mg/mL. This was chosen as it was 
within the tolerance range of the chickens if the gel degraded and released the drug faster 
than expected. The butorphanol level was also high enough that if the release rate was 
slower than expected, the levels present in the serum would remain detectable. 
The results from the pilot studies showed that the release rate of the hydrogel was higher 
than desired. However, due to limited amounts of available serum and complications with 
the HPLC, the results were too variable for detailed analysis and were therefore discarded. 
4.5.2.2 Primary study preparation 
After the pilot study, it was discovered that with some changes in the processing steps to 
form nanocellulose a suitable hydrogel could be produced. The problem with the low 
concentration of the hydrogel was removed by improved processing of the nanocellulose 
fibrils and alterations to the hydrogel formation technique, disrupting any nanocellulose 
clumps present in the hydrogel. 
With the higher concentration of hydrogel now available for consideration, more 
modifications could be investigated. After further analysis and experimentation, it was 
found that it was possible to form a 3 m/V% 1:9 NC:SA gel with 1 mL of 1% CaCl2. The 
hydrogel was evenly dispersed within the solution, had a viscosity that was low enough 
to be easily injected and displayed the best release rate in the RO H2O study. 
The hydrogel was then tested in-vitro in chickens as discussed in 3.3 and analysed by the 
techniques detailed in 3.4 and 3.5. 
4.5.3 Hydrogel release in RO H2O 
The hydrogel release rates were measured against the butorphanol standard curve to 
provide context to the area and height measurements from the sample peaks. The peak 
area vs concentration graph had the linear trendline with the R2 value closest to 1. The 





This reduced the risk of misinterpreting the HPLC results for the samples and clearly 
showed that the inter-day accuracy of the samples was high. The area variation was below 
2% for the area samples with the exception of the 250 ng sample, this had an outlier 
increasing the variation to ≈ 4% (Table 4). The peak height inter-day variation was lower 




Graph 1: Butorphanol level vs HPLC peak area 
Graph 2: Butorphanol level vs HPLC peak height 
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Butorphanol Average Area Average Height Area Variation % Area variation Height Variation % Height variation 
100ug 2.58 * 107 1.094 * 106 2.22 * 103 0.203 186 0.0170 
10ug 2.77 * 106 1.54 * 105 285 0.184 18.6 0.0121 
1ug 2.77 * 105 1.65 * 104 312 1.85 1.07 0.00650 
500ng 1.53 * 105 8.79 * 103 173 1.93 0.749 0.00852 
250ng 8.82 * 104 4.70 * 103 192 3.93 11.3 0.240 
125ng 5.06 * 104 2.50 * 103 29.3 1.16 1.39 0.0555 
 
The butorphanol levels of the samples were calculated using the STD butorphanol 
standard curve (Table 4). The concentrations taken from the STD standard curve had to 
be adjusted to take into account the removal of 1 mL of sample and its subsequent 
replacement with RO H2O which diluted the total solution.  
The samples did contain a higher drug concentration then the highest STD butorphanol 
standard curve concentration but the linear nature of the previous results and previous 
experimentation with higher concentrations made this assumption reliable.34 
4.5.4.1 NC-SA gel release 
The results showed that the hydrogel crosslinked with 1% CaCl2 had the slowest 
consistent release rate in the RO H2O with the 0.5% and 1.5% CaCl2 having faster release 
rates (Graph 3, Table 5). The 0.5% hydrogel was likely the weakest matrix and when 
exposed to large amounts of pressure from the swelling, the matrix degraded resulting in 
the encapsulated drug being released. 
The 1.5% CaCl2 gel produced the densest hydrogel. This meant that the ratio of 
butorphanol on the surface to encapsulated within the matrix was believed to favour the 
surface area. This would result in the observed rapid release of the butorphanol into the 
solution while the physical nature of the hydrogel was largely unchanged over time.  
 
  
Table 4: Butorphanol standard solutions with variance and percentage variance. The low variance values show that the inter-






























Graph 3: Butorphanol concentration calculated from the peak height vs time for hydrogels with various CaCl2 concentrations. The 
1% CaCl2 produced the best release rate, shown as the orange trendline. 
 
Graph 4: Butorphanol concentration calculated from the peak area vs time for hydrogels with various CaCl2 concentrations. The 




Table 5: HPLC results from hydrogel release rates within RO H2O with various CaCl2 concentrations of 
crosslinking. Adjusted to account for the removal of the 1 mL samples and replacement with 1 mL RO H2O. 
0.5% CaCl2 












0.25 135 135 135 135 
0.5 243 210 240 207 
1 231 205 226 201 
2 270 221 262 214 
4 294 238 283 229 
6 296 238 282 227 
12 275 219 259 207 
24 278 222 260 208 
1% CaCl2 
Alginate 












0.25 164 158 164 158 
0.5 232 206 230 204 
1 255 213 250 209 
2 255 213 248 207 
4 281 226 270 217 
6 292 237 278 226 
12 291 236 275 223 
24 304 247 284 231 
1.5% CaCl2 
Alginate 












0.25 131 128 131 128 
0.5 145 153 144 152 
1 290 246 284 241 
2 286 243 278 236 
4 290 251 279 241 
6 282 234 268 223 
12 283 236 267 223 
24 265 221 248 207 
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4.5.4.2 Chitosan-nanocellulose hydrogel release 
The chitosan-nanocellulose gel had an almost instant release rate, the butorphanol was 
completely released into the solution within the first 30 minutes. This was likely due to 
the hydrogel matrix not completely forming. This meant that the butorphanol is released 
immediately and taken into the solution.  
4.6 Animal trials 
Broiler chickens were used as the model avian species due to their low cost, the ease of 
management, low maintenance requirements, high availability and prior ethical 
permission being already achieved. The traditional therapeutic range for butorphanol in 
broiler chickens is 50-80 ng/mL which is far higher when compared to other common 
mammalian species.34 
The broiler chickens were subcutaneously injected under aseptic conditions to prevent 
infections which may influence the serum levels or cause the animal distress. Serum 
samples were obtained at regular time intervals in order to determine the release rate of 
the drug and retention within the chicken’s system. 
The 6 mg/kg dosing of the chickens ensured that the chickens would not be overdosed 
and that the size of the chicken would not affect the overall concentration of butorphanol 
present in the serum. This is based on the manufacturer’s guidelines for the commercial 
butorphanol injection recommendation. It was also assumed that the hydrogel would 
release the drug slower than the commercial butorphanol, or at worst the same rate as the 
commercial solution and therefore would not be an issue.  
The chickens were provided with a constant supply of feed and water to reduce the stress 
on the animals and reduce the effect of diet upon the chicken serum results. The chickens 
were kept in a thermally stable area and had a radio playing to acclimatise the chickens 







The injection caused no visible inflammation (Fig 23) or discomfort to the chicken as 
expected due to the biocompatible nature of the hydrogel. There was a small lump present 
where the hydrogel had been subcutaneously injected. This was believed to be the 
hydrogel itself rather than any swelling or inflammation due to the lack of discolouration 
or excessive heat. The chickens that were injected with the commercial butorphanol (Fig 
24) also showed no adverse reactions. 
The lump was not present after 48 hr and was believed to have been degraded, disrupting 
the hydrogel matrix structure and breaking up the polymer chains. After testing had been 





Figure 23: Chicken neck 30 min after injection with butorphanol hydrogel. The small lump present is the 
injected hydrogel. No inflammation was observed. Red arrow indicates injection site. 
Figure 24: Chicken neck 30 min after injection with commercial butorphanol. No lump present and no 
inflammation observed. Red arrow indicates injection site. 
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4.6.1 Sample collection issues 
When collecting the samples there were numerous issues encountered due to the nature 
of the animals examined. When inserting the catheters, the chickens were mildly 
distressed due to human handling. This resulted in complications such as the animal 
kicking out before the catheter could be secured to the leg, knocking out the catheter and 
damaging the veins. Subsequent catheters then had to be implanted into the alternate leg 
or abandoned for manual blood sampling. 
There were also difficulties extracting blood samples. The catheter was sometimes 
compressed or bent preventing blood flow. The heparin generally prevented clotting 
within the catheter and allowed easy extraction of the blood but occasionally there would 
be a blood clump formed that blocked the catheter. 
After collection had begun, the catheter could no longer be replaced; it would require 
professional assistance and would increase the risk of harming the chicken. If the catheter 
was knocked loose the subsequent blood samples were taken by direct injection of the 
needle into the veins in the leg. This was performed by Aline Alberti Morgado.  
The centrifugation step was to remove unwanted components of the blood such as 
haemoglobin and fibrin clots while leaving the serum containing butorphanol unaffected. 
However, the nature of the blood samples changed depending on the stress levels of the 
animal, resulting in vasoconstriction, this increased the blood pressure. This caused some 
blood samples to contain different levels of haemoglobin, this meant that the same amount 
of blood sample to have proportionally less serum. This resulted in some samples 
containing less serum and therefore reduced the amount available for subsequent testing. 
This problem was reduced by taking a larger volume of blood but this required larger 
broiler chickens to be able to tolerate the associated blood loss. The larger birds were 
considerably obese and were therefore more prone to health problems associated with 
their weight and the stress of handling. This also resulted in the death of a total of three 
chickens before and during the testing process, one of which perished before any 




4.7 Serum analysis 
The pilot study chicken serum samples provided for analysis and the samples extracted 
as part of the primary study were not always uniform. The volume of serum, colour and 
consistency varied dramatically for the supplied samples from the pilot study. The 
primary studies samples were relatively uniform with some mild variation in the volume 
and colouration.  
Samples from both studies were occasionally contaminated with small amounts of blood, 
shown by a darker red/brown coloured serum. Other serum samples were clear but had a 
large clear solid, believed to be a fibrin clot produced by amalgamation of residual 
amounts of fibrinogen present after centrifugation.  
The pilot study samples had problems with clotting reducing the volume of usable serum. 
This prevented the overall SPE extraction being done in duplicate for all of the supplied 
samples. There were also some samples that were not supplied due to them being 
misplaced or the chicken’s catheter being removed by the chicken’s actions. This meant 
that a detailed release rate could not be achieved using HPLC. 
This was improved in the primary study where a larger amount of blood was removed to 
increase the amount of available serum. There were also improved collection techniques 
used. These included taking care not to disturb the pellet after centrifugation when 
removing the serum. This reduced the presence of blood in the serum and maintaining a 
cold temperature of the samples before freezing at -20oC prevented degradation of the 
butorphanol levels in the samples. 
4.8 HPLC  
4.8.1 SPE  
The SPE cartridge extraction was performed under vacuum suction in order to reduce the 
hands-on time requirement. Without suction, the drip rate was roughly 1 mL/min and 
increased the risk of contamination due to long term exposure to the air ( ≈ 1 hr total 
exposure) .  
The RO H2O was added to dilute the plasma samples. This reduced the amount of initial 
serum required as the SPE cartridges function ideally with ≈ 1 mL of solution.  
64 
 
This also made it possible for blank serum samples to be spiked with known 
concentrations of butorphanol, replacing the RO H2O yet not altering the final volume of 
solution loaded into the SPE cartridges. 
The 2 M HCl was added to lower the pH of the solution, disrupting the binding of 
butorphanol to the various components of the serum.58 This allowed the butorphanol to 
be released into the solution as free butorphanol. The free butorphanol could then bind to 
the SPE cartridge. 
The drying of the cartridge after each wash step ensured there was no solution present in 
the cartridge which could alter the elution of the desired product or interfere with the 
subsequent wash step.  
The butorphanol was eluted with 100% methanol, disrupted the binding of the 
butorphanol to the SPE cartridge and releasing the butorphanol into solution. The solution 
was then collected into test tubes and dried under vacuum centrifugation to remove the 
methanol. This reduced the risk of contamination from methanol or remaining solvents 
that may change the peak height, area or retention time. The dried butorphanol was then 
reconstituted in mobile phase to prevent further contamination. 
4.8.2 HPLC Run Protocol 
A reverse phase C18 column was used because the butorphanol is less polar then the 
mobile phase, this increased the retention time of the butorphanol, allowing it to be 
separated from the other peaks evaluated at 202 nm. The temperature was increased to 
40oC as the nature of the mobile phase was causing high pressure in the column. This is 
because salts were precipitated and deposited onto the guard and HPLC columns at lower 
temperatures.  
This precipitation of salts caused clogging in the columns which required longer washing 
steps to remove. It would also occasionally cause the machine to shut down during longer 
runs making it impossible to run multiple chickens’ samples without running the cleaning 
protocol. The increased temperature also decreased the retention time, the higher pressure 
caused the butorphanol to be released sooner. By lowering the pressure, the butorphanol 




The HPLC column allowed separation of the butorphanol peak from the other compounds 
present in the blood without requiring an expensive mobile or solid phase. The column 
could be cleaned quickly and thoroughly to prevent carryover from previous experiments 
which may corrupt further results.  
The samples were kept in sealed HPLC vials at 4oC to reduce the risk of the sample 
degrading while waiting to be run. This decision was made based on previous publications 
which showed temporary storage at refrigerated temperatures (≈ 4oC) did not have 
adverse effects on the reconstituted sample of volatile substances.  
It was therefore assumed to have either a non or a limited effect upon the SPE treated 
plasma samples.59 
The wavelength used to analyse the samples was chosen to be 202 nm. Other absorbances’ 
did have a larger butorphanol absorption peak but there were other peaks present at 
similar retention times. 202 nm was chosen as it provided the greatest definition of the 
butorphanol peak without the interference of unwanted peaks.  
These interfering peaks could corrupt the results by artificially increasing or decreasing 
the peak area or height.  
The phosphate buffer used was similar to the buffer used in previous chicken butorphanol 
analysis studies34 with the exception of lowering the pH to 4. This lowering of the pH 
reduced the amount of salt that precipitated on the column. 
These changes also caused the butorphanol peak retention time to increase from ≈ 13 min 
in the previous study34 to ≈ 14 min , separation of the peaks present in the mobile and the 
plasma was also more effective. The buffer had the pH balanced with the minimal amount 
of NaOH. This was done because the NaOH produced a small peak at a similar retention 
time to the butorphanol peak.  
As long as the amount of NaOH was very low, the peaks remained distinct and the 
butorphanol peak could be integrated with a high degree of accuracy. 
4.8.3 HPLC Analysis 
Injections of the chickens with the gel and commercial butorphanol solution was 
performed to provide context for the experimental results. The commercial formulation 
release rates were used as a baseline for determining the hydrogel release rate.  
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Examining the absorption and degradation rate of the commercial butorphanol could also 
be used to compare with the release rate of the butorphanol from the hydrogel into the 
chicken’s system.  
The butorphanol concentration of the serum samples was based upon the standard curve 
constructed from the butorphanol standard curve. 
By performing this experiment on a large sample size (6 chickens), the effect of the 
variations in the broiler chicken’s metabolisms was minimised. This allowed for 
percentage variations to be calculated with a higher degree of accuracy and the ability to 
identify and discard any outliers.  
When performing the pilot study, the samples were run in duplicate after SPE. This 
reduced the uncertainty for the samples but due to the lack of serum samples multiple 
SPE runs were not possible for the pilot study serum samples.  
This was deemed unnecessary as previous studies by Dr Preet Singh had found negligible 
variation in the SPE extractions.34 
The primary study samples were run in duplicate after SPE had been performed in order 
to minimise uncertainty. However, there was enough serum sample to rerun any results 
that differed dramatically from the expected results allowing for a far greater confidence 
in the results. Any outlier could be identified, re-tested and upon further testing produced 
results that agreed with the other samples. 
The variation in HPLC results was occasionally caused by spikes in pressure as the guard 
column became clogged due to precipitation of salts or small molecules falling into the 
test tubes. This reduced the retention time, causing the butorphanol peak area and height 
to change as the HPLC run continued. This made the known concentration solutions of 
butorphanol impossible to determine so the samples were prepared again and rerun. 
The HPLC column was replaced after the samples from the primary study showed that 
after 4 chicken gel samples and 5 chicken no-gel sets had been run and dramatic variations 
in peak height and area were observed.  
The new column had lower inter and intraday variation when the samples were re-run and 




4.8.4 New column 
This showed recovery rates of butorphanol similar to those reported34 and retention times 
that separated the butorphanol peaks from other, undesired peaks present near the end of 
the experimental run. The retention time was larger than the previous column and other 
reported times by roughly 1 minute but this is believed to be a result of the lower pH 
buffer used in the mobile phase and was considered acceptable.  
4.8.5 HPLC cleaning protocol 
The initial wash step involved removing the guard column and running RO H2O with 
high pressure to remove any water-soluble compounds present on the guard column. The 
HPLC column was then reattached and washed with a lower pressure run that lasted 30 
min to remove any remaining water-soluble compounds. These included any precipitated 
salts remaining on the column which could interfere with subsequent runs. 
The 50:50 acetonitrile:RO H2O cleaning solution was sonicated for 10 min to remove any 
air bubbles that may be present after the mixing step before being used in wash steps. 
These bubbles would otherwise have been taken into the feedlines and potentially would 
cause problems with the column by altering the column pressure and introducing more 
peaks in the UV analysis.  
The final cleaning step was run for 30 min to remove any remaining contaminants and 
prepare the HPLC column for temporary storage without the risk of damage to the column 
membrane. The water:acetonitrile mixture was used for short term storage and 100% 
acetonitrile would be used before prolonged storage (3+ months) 
4.8.6 HPLC sampling problems 
Inconsistencies with the 8 hr gel samples were believed to be caused by the needle 
calibration for the sample tray being off for the sample vials. This error occurred only in 
the 8 hr gel samples as the no-gel samples were loaded into a separate column on the 
sample tray when the HPLC runs were performed.  
Occasionally the sampler needle would not inject correctly into the vial, striking the edge 
of the glass insert and damaging the vial insert or causing the machine to automatically 
shut down, this then required longer cleaning times and the sample preparation to be 
repeated. To prevent this from reoccurring the final two vial slots in each column were 




The HPLC needle was also found to be bent and not taking up a consistent volume from 
the vials resulting in a large variation within the replicates of the samples. This helped to 
explain the large variation that had been present in the samples from the pilot study. This 
meant that the samples had to be repeated to reduce the variation. The samples analysed 
before December 2018 were therefore re-run with the new HPLC column and analysed. 
4.9 HPLC validation 
4.9.1 HPLC linearity 
The butorphanol standard curve showed that the butorphanol peaks produced by HPLC 
had a linear relationship to the concentration within the 1 µg/mL to 15.6 ng/mL standard 
curve (Graph 7). This relationship was reproducible with minor variation so it was 
decided that the samples only required 3 standards per run to reduce run times. The 15.6 
ng/mL sample had a greater degree of variation but was still within the acceptable range 
to produce a linear standard curve (Graph 5). 
The retention times of the butorphanol peak had a variance of ≈ 0.2 min (Graph 8, 9)). 
The longer the run was, the smaller the retention time became as the sedimentation of 
salts on the guard column caused minor increases in the pressure (≈ 0.1 – 0.2 mpa). The 
increased pressure caused the butorphanol to be released from the column faster, resulting 
in the lower retention time. 
The inter sample standards were used to determine if there was any change in the peak 
area and height during the experimental runs. They concentrations chosen were 500, 250 
and 125 ng/mL standards of butorphanol in the mobile phase. These standards were 
within the middle of the expected range for the chicken samples and could be extrapolated 
to calculate the concentration of butorphanol present in each sample. The standards used 
were above the minimum effective dose of 50-80 ng/mL.  
Any serum concentrations which were lower than the effective dose were not considered 
vital. The standards run during sampling were compiled to calculate the average peak area 
and height then graphed to determine to determine the linearity of the relationship. The 
R2 value of 1 (Graph 5,6) showed that the peak area and peak height of the butorphanol 
standards had a linear relationship to the concentration. This showed that the relationship 
was consistent and could therefore be trusted for use in determining the butorphanol 
concentration in the chicken serum samples.  
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4.9.2 HPLC specificity 
The inter-day variances were calculated (Table 4) and showed that there was very little 
variation present. Any variation was likely a result of the pressure changes which 
generally occurred as more samples were run. 
The intra-day variation was determined and showed that there was a very low variance 
(Table 6). This reinforced the idea that the serum results from different days could be 
trusted to contain limited variation. 
Table 6: Intra-day variation of butorphanol standards including percentage variance and average areas with heights. The low 
















4.31 * 104 2.37 * 103 55.0 3.30 0.127 0.141 
250 
ng/mL 
8.81 * 104 4.74 * 103 335 17.0 0.379 0.359 
500 
ng/mL 
1.75 * 105 9.41 * 103 224 15.3 0.128 0.162 
Graph 5: Butorphanol stand curve for 125 ng/mL 250 ng/mL and 500 ng/mL vs HPLC peak area. 




Graph 6: Butorphanol stand curve for 125 ng/mL 250 ng/mL and 500 ng/mL vs HPLC peak height. 

















Total average peak height vs Butorphanol 
concentration
Graph 7: Butorphanol standard curve 15.6 ng/mL → 1 mg/mL, concentration vs HPLC peak height. 
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Graph 8: Chromatograph of four butorphanol spiked plasma standards and blank plasma. The area highlighted is the butorphanol peak. Minor 
variations in pressure resulted in slightly different retention times. The higher intensity of the 15.6 curve was due to sedimentation of salts within the 




Graph 9: Chromatograph of the three butorphanol standards in mobile phase. The area highlighted is the butorphanol peak. Minor variations in 
pressure resulted in slightly different retention times. 
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The blank plasma samples and a sample of mobile phase were run at the beginning of 
every chicken sample run to ensure that there was no carryover from previous runs or 
peaks occurring with the same retention time as the butorphanol peak. The results showed 
that the majority of blank plasma and mobile phase runs had no peaks present. The few 
samples that did had very small peaks.  
When the column was re-washed and the samples re-run, no extraneous peaks were 
present. This indicated that there could be some carryover but the risk was very low and 
the effect on the final results was determined to be negligible. 
The experimental results (Graph 8,9) show that the lower limit of quantification for the 
butorphanol standards and spiked plasma samples was 15.6 ng/mL. 
4.10 Primary Study 
4.10.1 Gel release rate 
The gel release rates were determined from analysis of the chicken serum samples using 
SPE and HPLC. The gel release rate HPLC results had to be further processed to produce 
an accurate reading for the butorphanol level in the sample. The samples were dried and 
then reconstituted so even if the recovery rate from the SPE cartridges was 100% and 
there was no loss during the processing steps. The final concentration will be higher as 
the original 300 µL of sample were reduced to a 200 µL final volume.  
The hydrogel was also suspended in commercial butorphanol and swelled to encapsulate 
the drug. However, this resulted in the concentration in the hydrogel being lower than the 
commercial solution due to a supernatant dilution factor caused by the hydrogel itself. 
This potentially caused the lower concentrations of butorphanol recorded at 15 min, 30 
min and 1 hr when compared to the commercial solution.  
The gel release rates were based on the average of all consistent serum samples from the 
chickens injected with the butorphanol hydrogel and the commercial butorphanol 
solution.  
After subcutaneous injection, the butorphanol was either released into the tissue from the 
hydrogel or was already present as a stock solution. It then passed through the chicken’s 
muscle tissue and was taken up into the blood supply. 
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 The release rates show that in the initial time points (15 min, 30 min, 1 hr) the commercial 
solution was released into the blood supply at a far higher rate than that of the hydrogel 
(Graph 10, 11).  
This is because the hydrogel must release the butorphanol from the gel matrix into the 
surrounding tissue before it can pass into the blood stream, therefore lowering the uptake 
rate. 
After 1 hr, the serum samples from the chickens injected with the hydrogel had higher 
butorphanol levels within their serum then the chickens injected with the commercial 
butorphanol solution. After 4 hrs had passed the serum levels from the commercial 
injection had dropped below the minimum effective dose level (Graph 12). 
The chickens injected with the hydrogel had a butorphanol level remaining above the 
effective dose level up to 26.5 hrs where the level then dropped below the minimum 
effective dose level and was no longer deemed effective.  
4.10.2 Pharmacokinetic analysis 
Pharmacokinetic parameters were determined using noncompartmental analysis (Table 
7,8). The elimination rate constant (lambda-z), maximum plasma concentration (Cmax), 
time to achieve Cmax (Tmax), half-life (t1/2) and clearance of drug (Cl/F) were determined 
directly from the plasma concentration data. The area under the curve (AUC) and the area 
under the first moment (AUMC) were determined using the linear trapezoidal method. 
Mean residence time (MRT) was calculated as AUMC/AUC.  
The elimination rate constant is a pharmacokinetic term referring to the rate the drug is 
removed from the system. The average results showed that the lambda-z level was higher 
for the NG samples when compared to the gel samples (0.77 1/hr vs 0.06 1/hr). This 
suggested that the gel continued to release the drug over a far longer period then the 
commercial butorphanol. The drug was removed via degradation within the liver and 
absorption into the cerebral and spinal tissue.  
The half-life of butorphanol is the time when the concentration of butorphanol in the 
serum is half the maximum concentration (Cmax). The half-life within the system is far 
higher in the serum samples from the chickens injected with the hydrogel (12.25 hr vs 1.5 
hr). The higher half-life correlates with the slower release rate of the butorphanol from 
the hydrogel.  
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As the release rate from the hydrogel decreases with time, the systems breakdown of the 
butorphanol would be able to catch up. This reduces the total amount of butorphanol 
within the system producing the observed half-life.    
The Tmax was the time in hours it took to achieve the maximum concentration within the 
serum samples (Cmax). There was little observed difference between the Tmax averages 
from the chicken serum samples (0.5 hr gel vs 0.4 hr no gel). This indicates that the Tmax 
is primarily influenced by uptake from the subcutaneous tissue to the blood stream. The 
minor increase in Tmax time from the gel sample was likely caused by the hydrogels 
release rate.  
The Cmax is the maximum observed concentration (ng/mL) and was very similar between 
the gel and no gel serum samples. This suggested that the hydrogel contained a large 
amount of butorphanol on the peripheries where it could be easily released. The 
butorphanol was then absorbed into the blood stream at the same rates producing the 
similar maximum concentrations within the serum. 
The area under the curve (ng/mL * h) showed that the gel samples had a higher average 
concentration of butorphanol within the serum over the measured time period (5893 vs 
1449). The area under first moment (ng/mL * h^2) exhibited similar results (6438 vs 
1513) with the gel serum samples again producing the larger value. 
The area under the curve from 0 to infinity is the total area under the graph from time 0 
till infinity (ng/mL * h) and the area under the main curve to infinity is the total area under 
the main curve from time 0 to infinity (ng/mL * h).  
The mean residence time MRT (h) is the average amount of time a drug molecule remains 
within the system. It is calculated from the sum of all the residency times divided by the 
number of drug molecules.  
The clearance of drug (mg)/(ng/ml)/h is the rate the active drug is removed from the body. 
It is the rate at which the drug is eliminated divided by the plasma concentration of the 
drug. This is generally a constant rate. The hydrogel serum samples had a lower clearance 
rate (0.005 vs 0.016) which helped to explain why the butorphanol level within the serum 
remained above the minimum effective dose for a longer time. 
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Chicken Units Gel 1 Gel 2 Gel 3 Gel 4 Gel 5 Gel 6 Average Variation  Variation % 
Lambda_z 1/h 0.057160089 0.10123133 0.0566255 0.0566255 0.032949322 0.07718589 0.063629605 0.00702 9.93 
t1/2 h 12.12641876 6.847160679 12.24090182 12.24090182 21.03676587 8.980231764 12.24539679 1.59 11.5 
Tmax h 0.5 0.25 0.5 0.5 1 0.5 0.541666667 0.0929 14.65 
Cmax ng/mL 553.97 1086.812 1225.408 1225.408 1479.854 1221.49 1132.157 71.05 5.90 
AUC 0-t ng/mL * h 1679.269115 2073.944318 4778.329545 4778.329545 14890.83075 7162.46187 5893.860856 3319.79 36.03 
AUC 0-inf_obs ng/mL * h 1921.501241 2238.802174 5585.294258 5585.294258 15761.79039 7535.854209 6438.089421 3303.89 33.9 
AUMC 0-inf_obs ng/mL * h^2 16695.95116 23780.15676 61712.96966 61712.96966 493036.9925 73206.56528 121690.9342 230164.79 65.4 
MRT 0-inf_obs h 8.689013986 10.62182136 11.0491886 11.0491886 31.28051956 9.71443492 13.73402784 4.53 24.8 
Cl/F_obs (mg)/(ng/mL)/h 0.010304443 0.008844015 0.003974723 0.003974723 0.001484603 0.002866297 0.005241468 0.00196 27.2 
 
Chicken Units NG 1 NG 2 NG 3 NG 4 NG 5 NG 6 Average Variation  Variation % 
Lambda_z 1/h 1.92931204 1.100915569 0.562644864 0.409434766 0.406853261 0.230625614 0.773297686 0.442 36.4 
t1/2 h 0.359271681 0.629609754 1.231944384 1.692936793 1.703678566 3.005508233 1.437158235 0.516 26.4 
Tmax h 0.25 0.5 0.5 0.25 0.5 0.25 0.375 0.0417 10 
Cmax ng/mL 1833.413 1146.854 1192.335 776.5288 1207.245 676.3906 1138.7944 122.23 9.69 
AUC 0-t ng/mL * h 1653.885425 1490.84368 1495.39657 1275.137953 1611.373565 1168.186553 1449.137291 20.86 1.42 
AUC 0-inf_obs ng/mL * h 1699.487535 1514.129326 1651.857467 1325.487414 1661.795626 1228.662359 1513.569954 21.16 1.38 
AUMC 0-inf_obs ng/mL * h^2 1190.295019 1577.121061 2640.703632 2792.917078 2599.138582 4070.343921 2478.419882 346.03 12.25 
MRT 0-inf_obs h 0.700384672 1.041602612 1.598626809 2.107086834 1.564054292 3.31282544 1.720763443 0.409 19.22 
Cl/F_obs (mg)/(ng/mL)/h 0.014474952 0.016643228 0.014529099 0.019464538 0.014803264 0.019045102 0.016493364 0.000264 1.58 
Table 7: Summary of pharmaceutical analysis of Chickens treated with the hydrogel in the primary study. 








Graph 11: Chromatograph of serum from the chickens injected with the NC:SA hydrogel. The area highlighted is the butorphanol peak. 
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 Graph 12: Semi-Log graph comparing the butorphanol concentration of the serum samples over time. The blue is the serum results from the 6 chickens injected with the 3% m/V 1:9 NC-SA 
1% CaCl2 hydrogel. The red line is the serum results from the 6 chickens injected with commercial butorphanol. The shaded area is the range for the minimum effective dose (50-80 ng/mL). 





The original aims of this project were to produce cellulose at a nano scale and then 
develop a hydrogel. This hydrogel would be based upon a composite of crosslinked 
nanocellulose monomers and traditional hydrogel materials. The first year primarily 
focused upon production of nanocellulose from hemp fibres and G. xylinus in preparation 
for hydrogel production and analysis.  
The microfibrilated cellulose was successfully extracted from the hemp fibres and then 
TEMPO oxidised to form nanofibrilated cellulose. The cellulose contained carboxylate 
groups, ideal for crosslinking interactions. The bionanocellulose was produced from G. 
xylinus but the yield was considered too low for further hydrogel production. 
The hydrogels were then produced from various ratios of nanocellulose and traditional 
hydrogel materials. This was done to determine the ideal composition for swelling and 
release of encapsulated drugs. The water release rates showed that the hydrogel required 
nanocellulose to stabilise the gel matrix when suspended in RO H2O.   
Chitosan was briefly examined but was not explored in detail due to the limited time 
available. The pure chitosan hydrogel lacked the mechanical stability when submerged in 
RO H2O, even when crosslinked with CaCl2. Composite crosslinked hydrogels composed 
of chitosan and nanocellulose had release rates of butorphanol in RO H2O that were too 
high for prolonged drug treatment. 
The ideal composition was found to be a 3% m/V 1:9 NC:SA hydrogel that had been 
crosslinked with 1% m/V CaCl2. This hydrogel could swell to a large extent, without 
breaking up the hydrogel matrix. The release rate of encapsulated butorphanol was also 
lower and more consistent than that of the other compositions.  
Once the ideal hydrogel had been identified and produced, in-vitro testing in chickens 
was conducted. This was the primary focus of the second year. The hydrogel was 
compared to a solution of commercial butorphanol that had an identical concentration and 
was injected in the same manner. The chickens were of very similar age and weight. They 





 The in-vivo testing showed very promising results. The hydrogel treated chickens had a 
butorphanol serum level capable of producing an analgesic effect for 26.5 hrs. This was 
compared to the commercial solution which had the butorphanol level drop below the 
effective dose after 4 hrs had passed.  
When this is compared to the alternative delivery mechanisms detailed in 2.6.2.2, the 
hydrogel has overcome many of the existing problems. The hydrogel is easily injected 
and rapidly begins to release butorphanol into the system, inducing an analgesic effect 
within 15 min which is preferable to the 6-12 hrs required by the osmotic pumps. The 
analgesic effect lasted far longer than the effect produced by the polyoxomer gel and the 
preparation was less intensive then the liposomal formulation. 
Overall the aims of the project had been achieved and surpassed with in-vitro and in-vivo 
analysis of the produced nanocellulose based hydrogel conducted. The results showed 
that the desired release rate of butorphanol had been achieved with further avenues of 
research discovered. 
6. Future Work 
The results of this thesis have shown that NC-SA hydrogels present possibilities for 
prolonged drug release in chickens when administered subcutaneously. The release rate 
was lower than the commercial butorphanol for the first hour, yet maintained a release 
rate at the required level for an analgesic effect for a longer time. The amount of 
butorphanol present in the serum over the initial time periods was low which means the 
initial concentration of butorphanol in the hydrogel could be increased without risking 
overdosing the chicken. 
 Increasing the concentration of butorphanol within the hydrogel may improve the release 
rate time if the butorphanol remains encapsulated in the hydrogel matrix. This would 
result in a higher butorphanol level within the serum producing an analgesic effect for a 
longer time period. 
The hydrogel composition was restricted by the viscosity of the hydrogel and the 
availability of nanocellulose fibrils. The nanocellulose content of the hydrogel could be 
increased to examine the release rate of hydrogels that possess a higher ratio of 
nanocellulose to sodium alginate. The increase in nanocellulose content could then alter 
the required amount or nature of crosslinking.  
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This may alter the viscosity of the solution allowing higher concentration hydrogels to be 
injected or the release rate of different drugs to be altered.  
The project focused on nanocellulose with sodium alginate hydrogels due to the time and 
resource restrictions. However, there is evidence in the literature that 
nanocellulose/chitosan blend hydrogels can be used for drug delivery and therefore could 
present a potential further avenue of research.  
The nanocellulose/chitosan hydrogel produced in the project showed limited promise as 
the butorphanol release rate with CaCl2 crosslinking was very high. This avenue was not 
explored as the NC:SA hydrogel showed a superior butorphanol drug release rate and 
mechanical stability so was seen as the more promising hydrogel. 
Another potential research avenue is to alter the crosslinking agent to increase the strength 
of the hydrogel matrix while maintaining a viscosity suitable for injection. The project 
used CaCl2 as a crosslinking reagent. The Ca
2+ ions crosslink the carboxyl groups present 
on TEMPO oxidised nanocellulose and sodium alginate.  
This means that other ions such as Mg2+ from MgCl2 could be used as a crosslinking 
reagent, the different ion size may allow the monomers to be crosslinked more closely 
together. This would reduce the pore size of the hydrogel limiting the swelling profile and 
increasing the density, this could produce a more stable hydrogel with a lower release rate 
but may also prevent the uptake of larger drug molecules.  
Chemical crosslinking through hydrolysable or metabolisable chemicals could also be 
considered such as using amides or ester groups. This would produce a far more rigidly 
structured hydrogel matrix and could provide more research opportunities for 
crosslinking reagents. The chemicals must be biodegradable and not induce an immune 
response by the target animal. 
The final potential change to the hydrogel itself is to alter the pH of the solution, many 
smart hydrogels exhibit different swelling profiles dependant on the pH of the solution. 
Increasing the pH would reduce the amount of available carboxyl groups, reducing the 
strength of crosslinking and mechanical strength. Lowering the pH would increase the 




By altering the pH of the hydrogel or injecting into areas which have a different pH, the 
release rate of the hydrogel could be altered to maximise the efficiency of release. 
Ideally the hydrogel would be tested on a larger variety of avian species to determine its 
viability for veterinary treatments. The chickens provided a strong groundwork for the 
idea of the hydrogel as a prolonged treatment for avian pain. The various metabolisms of 
different bird species upon the hydrogel was not investigated and would present the most 
likely future for in-vivo studies. If the results were similar over multiple avian species, 
expanding the treatment to mammals would be the next logical step. 
The non-selective uptake nature of the hydrogels allows for the potential for other opioids 
or water-soluble drugs to be loaded into the hydrogel. This makes nanocellulose 
hydrogels a good candidate for alternative drug release strategies with the other drugs 
also being capable of altering the release rates and release time of the drug.  
This potentially makes the hydrogel suitable for delivery of other drug species with 
greater efficiency than butorphanol, especially drugs that were capable of binding to the 
nanocellulose or sodium alginate backbones directly. This binding would reduce the 
release rate of the drug allowing larger concentrations to be added safely to the hydrogel 
without risking overdosing. 
The possibility of loading more than one drug into the same hydrogel could make dual 
therapy possible without requiring multiple injections or administration strategies. This 
would reduce the risk of infection and minimising the discomfort on the patient in 
addition to the amount of hands on time required by trained professionals for 
administration.  
One of the primary alternative drugs under consideration was salicylic acid, a non-
steroidal anti-inflammatory drug. Combining the salicylic acid with an opioid could 
provide treatment for arthritic pain. The salicylic acid would reduce the inflammation 
placing pressure upon the joints and the opioid would reduce the discomfort experienced.  
Nanocellulose composites could potentially be used for long term pain release in 
mammalian species. The non-toxic nature of the hydrogel and wide variety of potential 




The possibility also exists for nanocellulose composite hydrogels to be used for treatment 
of people suffering from osteoarthritis. The loading of an analgesic and non-steroidal anti-
inflammatory drug into the same hydrogel could provide the long-term anti-inflammatory 
and analgesic treatment required to control the swelling and pain. This could make 
subcutaneous treatment with hydrogels a viable alternative to cortisone injections 
currently used by medical practitioners to treat arthritis without the spike in pain 
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Appendix i. Timesheets for chicken sampling (Gel). 
  
Chicken Day G1 Hours since start G2 Hours since start G3 Hours since start 
Start Time Wed 27/09/2017 10:10 0 27/09/2017 10:12 0 27/09/2017 10:14 0 
15min Wed 27/09/2017 10:27 0.283333333 27/09/2017 10:30 0.3 27/09/2017 10:33 0.316666667 
30min Wed 27/09/2017 10:40 0.5 27/09/2017 10:43 0.516666667 27/09/2017 10:45 0.516666667 
1hr Wed 27/09/2017 11:11 1.016666667 27/09/2017 11:13 1.016666667 27/09/2017 11:15 1.016666667 
2hr Wed 27/09/2017 12:10 2 27/09/2017 12:12 2 27/09/2017 12:15 2.016666667 
4hr Wed 27/09/2017 14:18 4.133333333 27/09/2017 14:20 4.133333333 27/09/2017 14:23 4.15 
8hr Wed 27/09/2017 18:12 8.033333333 27/09/2017 18:24 8.2 27/09/2017 18:32 8.3 
16hr Thu 28/09/2017 2:05 15.91666667 28/09/2017 2:08 15.93333333 28/09/2017 2:14 16 
24hr Thu 28/09/2017 8:42 22.53333333 28/09/2017 8:45 22.55 28/09/2017 8:51 22.61666667 
36hr Fri 29/09/2017 0:27 38.28333333 29/09/2017 0:30 38.3 29/09/2017 0:33 38.31666667 
48hr Fri 29/09/2017 9:35 47.41666667 29/09/2017 9:37 47.41666667 29/09/2017 9:41 47.45 
72hr Sat 30/09/2017 9:42 71.53333333 30/09/2017 9:49 71.61666667 30/09/2017 9:54 71.66666667 
96hr Sun 1/10/2017 9:34 95.4 1/10/2017 9:39 95.45 1/10/2017 9:43 95.48333333 
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 Chicken  Day G4 Hours since start G5 Hours since start G6 Hours since start 
Start Time Thu 28/09/2017 9:39 0 28/09/2017 9:41 0 28/09/2017 9:42 0 
15min Thu 28/09/2017 9:52 0.216666667 28/09/2017 9:58 0.283333333 28/09/2017 10:00 0.3 
30min Thu 28/09/2017 10:09 0.5 28/09/2017 10:12 0.516666667 28/09/2017 10:13 0.516666667 
1hr Thu 28/09/2017 10:38 0.983333333 28/09/2017 10:41 1 28/09/2017 10:52 1.166666667 
2hr Thu 28/09/2017 11:46 2.116666667 28/09/2017 11:49 2.133333333 28/09/2017 11:52 2.166666667 
4hr Thu 28/09/2017 13:41 4.033333333 28/09/2017 13:45 4.066666667 28/09/2017 13:50 4.133333333 
8hr Thu 28/09/2017 17:38 7.983333333 28/09/2017 17:43 8.033333333 28/09/2017 17:48 8.1 
16hr Fri 29/09/2017 1:04 15.41666667 29/09/2017 1:10 15.48333333 29/09/2017 1:16 15.56666667 
24hr Fri 29/09/2017 8:45 23.1 29/09/2017 9:27 23.76666667 29/09/2017 9:31 23.81666667 
36hr Sat 30/09/2017 0:14 38.58333333 30/09/2017 0:23 38.7 30/09/2017 0:26 38.73333333 
48hr Sat 30/09/2017 9:49 48.16666667 30/09/2017 10:02 48.35 30/09/2017 10:05 48.38333333 
72hr Sun 1/10/2017 9:49 72.16666667 1/10/2017 9:55 72.23333333 1/10/2017 10:00 72.3 
96hr Mon 2/10/2017 9:43 96.06666667 2/10/2017 9:56 96.25 2/10/2017 9:58 96.26666667 





Appendix ii. Timesheets for chicken sampling (No Gel). 
 
Chicken Day NG1 Hours since start NG2 Hours since start 
Start Time Fri 29/09/2017 9:55 0 29/09/2017 9:56 0 
15min Fri 29/09/2017 10:10 0.25 29/09/2017 10:11 0.25 
30min Fri 29/09/2017 10:26 0.516666667 29/09/2017 10:28 0.533333333 
1hr Fri 29/09/2017 10:55 1 29/09/2017 10:57 1.016666667 
2hr Fri 29/09/2017 11:53 1.966666667 29/09/2017 11:56 2 
4hr Fri 29/09/2017 14:03 4.133333333 29/09/2017 14:05 4.15 
8hr Fri 29/09/2017 17:57 8.033333333 29/09/2017 18:00 8.066666667 
16hr Sat 30/09/2017 0:50 14.91666667 30/09/2017 0:53 14.95 
24hr Sat 30/09/2017 10:13 24.3 30/09/2017 10:15 24.31666667 
36hr Sat 30/09/2017 21:46 35.85 30/09/2017 21:48 35.86666667 





Chicken Day NG3 Hours since start NG4 Hours since start NG5 Hours since start NG6 Hours since start 
Start Time Mon 2/10/2017 0 2/10/2017 0 2/10/2017 0 2/10/2017 0 
15min Mon 2/10/2017 0.25 2/10/2017 0.25 2/10/2017 0.266666667 2/10/2017 0.266666667 
30min Mon 2/10/2017 0.6 2/10/2017 0.65 2/10/2017 0.666666667 2/10/2017 0.7 
1hr Mon 2/10/2017 1.033333333 2/10/2017 0.966666667 2/10/2017 1.033333333 2/10/2017 1.05 
2hr Mon 2/10/2017 2.016666667 2/10/2017 2.033333333 2/10/2017 2.05 2/10/2017 2.05 
4hr Mon 2/10/2017 4.033333333 2/10/2017 4.033333333 2/10/2017 4.033333333 2/10/2017 4.05 
8hr Mon 2/10/2017 7.933333333 2/10/2017 7.95 2/10/2017 7.966666667 2/10/2017 8 
16hr Tue 3/10/2017 15.51666667 3/10/2017 15.56666667 3/10/2017 15.58333333 3/10/2017 15.6 
24hr Tue 3/10/2017 23.75 3/10/2017 24.11666667 3/10/2017 24.36666667 3/10/2017 24.21666667 
36hr Wed 4/10/2017 38.35 4/10/2017 38.38333333 4/10/2017 38.4 4/10/2017 38.43333333 
48hr Wed 4/10/2017 47.98333333 4/10/2017 47.98333333 4/10/2017 48 4/10/2017 48 
 
 
